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Abstract: Background 
There is good evidence that primary care referral to an open-group 
behavioural programme is an effective treatment for obesity, but little 
evidence on optimal treatment duration.  
Methods 
In this non-blinded parallel-group randomised controlled trial, we 
recruited participants (age ≥18 years, BMI ≥28 kg/m²) through 23 primary 
care practices in England. Participants were randomised using the study 
database in a 2:5:5 allocation to: brief weight loss intervention, a 
weight management programme (Weight Watchers®) for 12 weeks, or the same 
weight management programme for 52-weeks. We followed participants over 
two years. The primary outcome was weight at one year, analysed using 
mixed-effects models according to intention-to-treat principles adjusted 
for centre and baseline weight. In a hierarchical-closed-testing 
procedure we compared combined behavioural programme arms with brief 
intervention, then compared the 12-week and 52-week programmes. We 
conducted a within-trial cost-effectiveness analysis using person-level 
data and modelled outcomes over a 25-year horizon using microsimulation. 
Current Controlled Trials ISRCTN82857232.  
 
Findings 
Between 18th October 2012 and 10th February 2014, 1267 eligible 
participants were randomised to the brief intervention (211), 12-week 
programme (528) and 52-week programme (528). 823 (65%) completed an 
assessment at one year and 856 (68%) at two years. All participants were 
included in the analyses. At one year, mean weight change was -3·26 kg 
(brief intervention), -4·75 kg (12-week programme), and -6·76 kg (52-week 
programme). Participants in the behavioural programme lost more weight 
than those in the brief intervention [adjusted difference = -2·71 kg (95% 
CI -3·86,-1·55); p<0·0001]. The 52-week programme was more effective than 
the 12-week programme [adjusted difference= -2·14 kg (95% CI -3·05, -
1·22); p<0·0001]. Differences between groups were still significant at 
two years. No adverse events related to the intervention were reported. 
Over two years, the incremental cost-effectiveness ratio (ICER;compared 
with brief intervention) was £159/kg lost for the 52-week programme and 
£91/kg for the 12-week programme. Modelled over 25 years after baseline, 
the ICER for the 12-week programme was dominant compared with the brief 
intervention. The ICER for the 52-week programme was cost-effective 
compared with the brief intervention (£2498/QALY) and the 12-week 
programme (£3804/QALY).  
Interpretation 
For adults with overweight or obesity, referral to this open-group 
behavioural weight loss programme for at least 12 weeks is more effective 
than brief advice and self-help materials. A 52-week programme produces 
greater weight loss and other clinical benefits than a 12-week programme 
and, although it costs more, modelling suggests it is cost-effective in 
the longer term. 
 
 
 
 
Dear Jennifer, 
 
We thank the reviewers for their positive appraisal and the constructive comments on our 
manuscript. Below, please find a point by point response to the questions raised by the reviewers. In 
addition to the edits requested by the reviewers, we have made a number of small changes. These 
are listed at the end of the response to reviewers.  We hope that you will agree that this response 
addresses the reviewers’ comments and we thank you for your continued consideration of our 
manuscript. 
 
Kind Regards 
 
Amy 
 
Response to the Reviewers. 
Reviewer #5: The inclusion of the 24mo and economic data greatly alleviates my primary concerns 
with this paper. The inclusion of these data have greatly strengthened the conclusions. 
 
p13 line 12 - "broadly generalizable" has been added to soften conclusions about sample 
representativeness. I feel as though clearer acknowledgement should be given about the high 
proportion of females. I appreciate that this is typical of weight management trials. However, in this 
section the authors refer to the "UK population" which is not 68% female. 
 
We believe ‘broadly generalizable’ is an appropriate term here, as although the gender split is not 
representative of the UK population, we identified no interaction between gender and intervention 
on weight loss. We have added a caveat to P13 L13 to reiterate that there are still a lower 
proportion of males than is seen in the UK population.  
 
The Table 4 heading needs to be adjusted to reflect presentation of 24mo data. 
This table heading has been amended 
 
 
Reviewer #7: The authors present findings from a randomised controlled trial comparing weight loss, 
other clinical and quality of life measures between participants referred to an extended weight loss 
programme and participants referred to a 12-week weight loss programme. Both arms are also 
compared with a brief intervention. The statistical analysis is thorough and appropriate and the 
authors have done a good job of addressing the reviewers' comments. However, there are still some 
questions that I think they should address in order to make the paper suitable for publication. 
 
Major points 
 
1. One issue that I don't think is sufficiently addressed in the manuscript is the fact that, by 
design, when outcomes are assessed at 12 and 24 months, the time lag from the end of the weight 
loss programme differs between the two weight management programmes (at the 12 month time 
point, the 12 week programme has finished 9 months earlier and the 52 week programme has just 
finished; at the 24 month time point, the 12 week programme has finished 21 months earlier and the 
52 week programme has finished 12 months earlier). Did the authors ever consider having an 
outcome measurement at the same time lag from finishing the intervention and comparing results at 
this time point between the two arms? Obviously this can't be added now and may not make sense 
from a programmatic point of view, but it might be interesting to think about whether the effects of 
a longer-term intervention are sustained over a longer period of time (after the intervention has 
ended) compared to the longer-term effects of a shorter-term intervention. Related to this, in the 
*Reply to Reviewers Comments
discussion the authors state "On average all groups regained some of the weight lost and at 2-years 
the difference in weight loss between the 12-week programme and the brief intervention was no 
longer significant, whereas the weight loss 1 in the 52-week programme was significantly greater 
than both other groups." Relating to the point above that this could just be because those in the 12-
week programme finished going to weight watchers longer ago than those in the 52 week 
programme, so this point could be mentioned. 
 
As the reviewer notes, the trial was designed to compare the cost-effectiveness of different length 
interventions at pre-specified time points over a 2 year period. It would not make sense to have 
different lengths of follow up for the different interventions. In addition, changing the timing of 
assessments based on intervention length could introduce problems with variable attrition rates 
over time and differences between groups in age at follow up. This issue is highlighted when we 
consider the brief intervention. End of intervention for the brief intervention group would be the 
end of the baseline appointment. 
 
2. The secondary outcome "triglycerides" was not listed in the protocol as far as I can see. 
While “triglycerides” are not specified, they are encompassed in the more general term “lipid 
profile”.  
 
3. "Potential interactions between intervention effects and gender, educational qualification 
and income were examined, as a recent review highlighted the lack of evidence of this type of 
programme on socio-economic inequalities". I think it could be made even more clear that these 
subgroup analyses were not planned at the start of the study (they are not in the protocol) but were 
instead added later on as new research was published. 
 
We have moved the description of this analysis to a new paragraph to make clear its separation from 
the protocol-specified trial analysis and we have edited to be clear that this was a post-hoc analysis. 
 
4. Outcomes "self-reported quality of life (EQ5D-3L) and health resource use at 3, 12 and 24 
months" are reported. I don't think it was clear in the protocol that these specific psychosocial and 
process measures would be included as outcomes (others are also listed but not mentioned in the 
manuscript, for example other psychosocial measures such as SRHI and VAS). It would be good if the 
authors could either mention these in the results of this paper or explain in a response why they're 
not included. Personally I think they don't have to be included in this paper as the protocol doesn't 
explicitly state that they will be, but it would be interesting to hear what the plans are. 
 
The psychosocial measures included in this trial were not designated as clinical outcomes. They were 
added to enable us to conduct future work on how baseline differences in these factors affect 
weight trajectories, how these factors change during and following a weight loss intervention, and 
how changes are associated with changes in weight. This is specified in the protocol. We have 
included self-reported quality of life and health resource use in this manuscript as these are relevant 
to the economic evaluation which was specified in the protocol. 
 
5. In the results, it is stated  "There were no differences between  intervention groups in the 
number of participants completing a 24-month assessment (p=0.21)." Please could the authors also 
include information on whether there were any differences at 12 months. 
 
There was a borderline statistical difference in attendance at 12 months. We have added this to the 
manuscript (P10. L12) 
“Using Pearson's Chi-squared test, there was a borderline statistically significant association 
between the percentage of participants attending the 12-month appointment and intervention 
group (p=0.047), though there was little evidence to suggest such an association for participants 
completing the 24-month assessment (p=0.212).”  
 
 
6. Reviewer 5 asked whether there were differences in demographic characteristics between 
those who did and didn't provide blood samples. I think it is also important to comment on whether 
there were differences in characteristics between those who were lost to follow-up and those who 
attended 3, 12 and 24 month visits. This would help with understanding the generalisability of 
findings. 
 
In response to this reviewer, we have examined interactions between intervention group and 
individual baseline characteristics (age, BMI, Sex, household income, ethnicity and education) for 
attendance at each study visit (3 months, 12 months and 24 months). Only two interactions were 
statistically significant (gender and intervention at 12 months (p=0.008), education and intervention 
group at 24 months (p=0.046)). However, neither interaction demonstrated a consistent pattern 
across visits. We have added a sentence to the paper to state that " Examination of the effect of 
individual characteristics on attendance by intervention group found no statistical evidence of bias in 
attendance over the study’s duration.”  P10 L16 
 
7. The authors need to make it clear in the methods that the comparisons between the BI and 
combined CP groups are one-sided tests, and the comparisons between the two CP groups are two-
sided tests. It is mentioned in the table (and in the protocol) but I think it should be stated in the 
statistical analysis methods as well. 
 
We have added this specification to the analysis section P8 L3-4 
 
8. I am not a modeller or health economist but the results from the 25 year modelling seem 
surprising to me. Since the general trend in all groups is for participants to regain the weight they 
have lost, can the longer time period for which the individuals in the 52 week intervention group are 
at a weight below their baseline (on average) really lead to such big improvements in terms of 
incident cases of disease, QALYs etc over a 25 year period? Will defer to an economist to assess this 
but I would be interested to know whether the authors were surprised by this? 
 
We were not overly surprised by the results of the modelling. Weight losses are similar to the 
Diabetes Prevention Programme, which saw a 27% reduction over 15 years, despite gradual weight 
regain. Naturally these are estimates based on a number of assumptions. However, our assumptions 
are relatively conservative (e.g. assuming 100% weight regain by 5 years).  
 
9. It seems surprising that "Only a tiny minority of participants in each arm used interventions 
that were not indicated by their randomisation." I found this slightly confusing as it implies that 
hardly anyone in the 12 week programme chose to carry on with it to say 52 weeks under their own 
steam (which to me would be contra-indicated by their randomisation)? But this isn't the case 
because later in the discussion figures on how many continued under their own cost are presented. 
Perhaps it should be made clear that this sentence is talking about use of other interventions during 
the period that participants were receiving the programme they were allocated to (if that is what is 
meant?) 
 
We have amended to be more specific about what we mean. “Only a tiny minority of participants in 
each arm used other NHS interventions or weight loss medications, and only a small proportion of 
participants who were assigned to the brief intervention group went on to use a commercial weight 
loss programme.” 
 
10. CONSORT checklist is not included. 
 
The CONSORT checklist is attached. 
 
Minor points 
 
1. In the abstract it states that "Behavioural programme participants lost more weight than 
brief intervention participants [adjusted difference = -2·71 kg (95% CI -3·86,-1·55); p<0·0001]." It 
would be helpful to explain what was adjusted for so that the abstract may stand alone. 
 
This has been added to the abstract P3 L13 
 
2. Out of interest, how many in the 52-week group were still attending at 24 months? 
17% - This is reported in Table 5 
 
3. Table 2 title "Table 2: Changes in weight from baseline (mean, SE) at 3, 12, and 24 months by 
intervention group using different assumptions about missing data" only seems to show results under 
the assumption of MAR… 
 
The title has been amended to be clear it only reports the main analysis 
 
4. Table 3. Would be useful to label which data in the table relate to the 5% and 10% loss. 
 
Apologies for this omission. This column has now been added to the table.  
 
 
 
Reviewer #8: As recognized by the authors, previous reviewers and editors, the addition of economic 
evaluation to this manuscript provides added insight into the relative value of these interventions. I 
commend the authors for presenting both a person-level cost-effectiveness analysis using data from 
the trial as well as completing a model-based cost-utility analysis over a 25 year time horizon. 
Based on the editors request I have restricted my commentary to the additional economic 
evaluations that have been supplemented to this manuscript  -  expanded manuscript body and new 
supplemental appendix. 
 
Major Comments 
* While it is clear in the manuscript body, I would suggest the authors more clearly state in the 
abstract that 2 economic evaluations were performed, one with a 2 year time-horizon using person-
level data from the trial and a second with a 25-year time horizon using microsimulation modelling. 
 
We have amended the abstract as suggested. P3 L16. 
  
* The authors offer insufficient detail regarding the model structure. What health states were 
modeled over the 25 year time horizon? As per ISPOR economic evaluation reporting guidelines 
(https://www.ispor.org/ValueInHealth/ShowValueInHealth.aspx?issue=3D35FDBC-D569-431D-8C27-
378B8F99EC67), a figure to show model structure is strongly recommended. 
*With respect to model inputs for the 25-year analysis, the authors must provide some description of 
QALY calculations beyond simply referencing the use of the Foresight: Tackling Obesities framework.  
From where were the utility weights drawn? Can the authors expand on how the population's disease 
incidence was projected? The manuscript body and appendix offer little insight into the model inputs. 
 
A figure illustrating model structure and an associated description have been added to section 4.1 of 
the Web Appendix to clarify the model structure and microsimulation process, specifically 
paragraphs 2 and 3. We have also added a table of the model inputs. 
 
* Characterization of uncertainty in the microsimulation model should be presented (e.g. cost-
effectiveness plane and cost-effectiveness acceptability curve) 
 
The  confidence limits that accompany the sets of output data in the web appendix represent the accuracy of 
the microsimulation (monte carlo errors) as opposed to the confidence of the input data (sensitivity analysis) 
itself. Errors around all of the input data were not available. Because this does not offer a complete picture of 
uncertainty, it would be preferable to only report the point estimates obtained, so as to avoid the uncertainty 
estimates being misinterpreted.  
 We have amended the Web Appendix (section 4.1 Methods): “The microsimulation model does not currently 
produce estimates of uncertainty based on input data statistics (sensitivity analysis). However, the model does 
produce uncertainty arising from the Monte Carlo process, representing the accuracy of the microsimulation 
itself.” 
 
Specific comments 
* "Cost per kg" or "cost/kg" is used throughout the manuscript and appendix when in fact, 
"incremental cost per kg lost" would be more appropriate. Those not familiar with economic 
evaluation may mistakenly interpret the "cost per kg" to reflect the cost associated with losing 1 kg 
associated with one weight loss intervention. In fact the authors are appropriately using the ICER 
(incremental cost effectiveness ratio or  incremental cost per kg lost in this case) as the primary 
outcome parameter. As an example, Figure A1 titled " Cost effectiveness plane - Cost per additional 
kg lost (2-year time horizon)" should be more clearly titled as "Cost effectiveness plane - Incremental 
cost per additional kg lost (2-year time horizon)" 
We thank the reviewer for highlighting this issue and have amended for clarity 
 
*In Appendix, point 4 - Long Term Cost-Effectiveness Modeling, 2nd paragraph: "For a given 
comparison of A vs B, negative ICERs indicate that the intervention is dominant in terms of cost-
effectiveness, over group B" This is not entirely true. A negative ICER may also reflect that A is more 
expensive and less effective than B, whereby B is dominant.  
 
This additional information has been added to the Web Appendix, section 4.1, for clarity.  
ADDITIONAL EDITS 
 
While completing the COI forms, Prof Jebb realised that her COI regarding the Rosemary Conley 
articles “timed out” this month, and so the sentence “Until January 2014, SAJ wrote a nutrition 
column for the Rosemary Conley Diet and Fitness magazine and received a fee.” has been removed 
from the COI section of the manuscript. P2  
We previously omitted a statement about adverse events from the body of the manuscript (it was in 
the abstract) so have added this on P7 and P12. 
We previously omitted the long term cost-effectiveness result for the 12-week programme from the 
discussion and the research in context panel, so we have added sentences on P13 and P21. 
With have highlighted our use of a flat rate cost in the cost-effectiveness analysis, as this is not 
always how this programme is charged and may overestimate real costs. P13. 
We have highlighted an additional limitation on P14 (the low completion of health care usage data) 
We have added updated references for the Diabetes Prevention Programme Study (reporting the 15 
year, rather than 10 year findings) on P15 and the UK Census Data P14.  
We have updated the literature review for the Research in Context Panel and changed the date in 
the manuscript to today’s date (P21). 
We have moved the sentence “Contrary to common criticisms that these interventions could 
exacerbate health inequalities, there was no evidence that the outcome of treatment is moderated 
by socioeconomic factors such as gender, education and income.” to be next to the weight loss 
outcomes, as this is the treatment outcome that we refer to. (P21) 
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Summary  1 
Background 2 
There is good evidence that primary care referral to an open-group behavioural 3 
programme is an effective treatment for obesity, but little evidence on optimal treatment 4 
duration.  5 
Methods 6 
In this non-blinded parallel-group randomised controlled trial, we recruited participants 7 
(age ≥18 years, BMI ≥28 kg/m²) through 23 primary care practices in England. 8 
Participants were randomised using the study database in a 2:5:5 allocation to: brief 9 
weight loss intervention, a weight management programme (Weight Watchers®) for 12 10 
weeks, or the same weight management programme for 52-weeks. We followed 11 
participants over two years. The primary outcome was weight at one year, analysed 12 
using mixed-effects models according to intention-to-treat principles adjusted for centre 13 
and baseline weight. In a hierarchical-closed-testing procedure we compared combined 14 
behavioural programme arms with brief intervention, then compared the 12-week and 15 
52-week programmes. We conducted a within-trial cost–effectiveness analysis using 16 
person-level data and modelled outcomes over a 25-year horizon using microsimulation. 17 
Current Controlled Trials ISRCTN82857232.  18 
 19 
Findings 20 
Between 18th October 2012 and 10th February 2014, 1267 eligible participants were 21 
randomised to the brief intervention (211), 12-week programme (528) and 52-week 22 
programme (528). 823 (65%) completed an assessment at one year and 856 (68%) at 23 
two years. All participants were included in the analyses. At one year, mean weight 24 
change was -3·26 kg (brief intervention), -4·75 kg (12-week programme), and -6·76 kg 25 
(52-week programme). Participants in the behavioural programme lost more weight than 26 
those in the brief intervention [adjusted difference = -2·71 kg (95% CI -3·86,-1·55); 27 
p<0·0001]. The 52-week programme was more effective than the 12-week programme 28 
[adjusted difference= -2·14 kg (95% CI -3·05, -1·22); p<0·0001]. Differences between 29 
groups were still significant at two years. No adverse events related to the intervention 30 
were reported. Over two years, the incremental cost-effectiveness ratio (ICER;compared 31 
with brief intervention) was £159/kg lost for the 52-week programme and £91/kg for the 32 
12-week programme. Modelled over 25 years after baseline, the ICER for the 12-week 33 
programme was dominant compared with the brief intervention. The ICER for the 52-34 
week programme was cost-effective compared with the brief intervention (£2498/QALY) 35 
and the 12-week programme (£3804/QALY).  36 
Interpretation 37 
For adults with overweight or obesity, referral to this open-group behavioural weight loss 38 
programme for at least 12 weeks is more effective than brief advice and self-help 39 
materials. A 52-week programme produces greater weight loss and other clinical benefits 40 
than a 12-week programme and, although it costs more, modelling suggests it is cost-41 
effective in the longer term. 42 
 43 
Funding 44 
 4 
 
This trial was funded by the National Prevention Research Initiative grant MR/J000493/1. 1 
The cost of the Weight Watchers® programme and the costs of blood sampling and 2 
analysis were funded by Weight Watchers International as part of an MRC Industrial 3 
Collaboration Award.   4 
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BACKGROUND 1 
The burden of disease attributable to excess weight places considerable strain on health 2 
care resources across the world.1,2 Behavioural weight management programmes are the 3 
first-line treatment for overweight and obesity, and although there is good evidence that 4 
some of these programmes can be effective, others are not.3 This may be due to 5 
differences in content and format of interventions, including the length of time support is 6 
provided. In the UK, the National Institute for Health and Care Excellence (NICE) public 7 
health guidance recommends that behavioural weight management programmes should 8 
last a minimum of 12 weeks4 and this is the standard length of the most commonly 9 
commissioned interventions.5 However, there is conflicting evidence about whether 10 
longer treatment duration would be more effective. 6,7 11 
Open-group behavioural weight loss programmes are among the most commonly 12 
commissioned programmes in the UK and evidence suggests these programmes are 13 
effective and cost-effective.3,8  The current trial was designed to directly compare 14 
whether 52-week referral to an open-group weight management programme would 15 
achieve significantly greater weight loss and improvements in a range of secondary 16 
health outcomes than the current practice of 12-week referrals, and be more cost-17 
effective.  18 
METHODS 19 
Study Design 20 
This was a multi-centre, non-blinded, multi-arm parallel groups randomised controlled 21 
trial with imbalanced randomisation (2:5:5), conducted in England. The full protocol is 22 
described elsewhere.9 23 
In brief, participants were recruited from 23 primary care practices across England 24 
between October 2012 and February 2014. Recruitment and follow up was conducted by 25 
three research centres: MRC Human Nutrition Research, Cambridge (coordinating 26 
centre), the University of Liverpool, and the University of Oxford. Cambridge and 27 
Liverpool teams recruited local practices and research staff conducted study visits at the 28 
research centre. Oxford recruited practices across southern and eastern England and 29 
practice staff (usually a research nurse) conducted study visits at the practice.  30 
Ethical approval was received from NRES Committee East of England (12/EE/0363). This 31 
trial was registered at Current Controlled Trials ISRCTN85485463 on 12th October 2012.  32 
Participants 33 
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Eligible participants (aged ≥18years; body mass index (BMI) ≥28 kg/m²) were identified 1 
through practice records. Exclusion criteria were: planned (within two years) or current 2 
pregnancy; previous or planned bariatric surgery; currently following a structured, 3 
monitored weight-loss programme; participating in other research that could confound 4 
outcome measures; eating disorder; non-English speaking or with special communication 5 
needs. Practices could exclude additional patients they felt it was inappropriate to invite 6 
but were asked to report reasons. These additional exclusions included terminal 7 
illness/palliative care, dementia, a severe mental health problem or learning difficulty, 8 
carer for a terminally ill relative, or recently bereaved. Patients were invited by letter and 9 
asked to contact the local study coordinator for telephone screening if they were 10 
interested in participating. Eligible and willing participants were given an appointment, 11 
where a member of the research team weighed them and measured their height to 12 
confirm eligibility before randomisation. Where more than one household member was 13 
eligible and interested in participating, the first to enrol was taken as the participant. All 14 
participants gave written informed consent.  15 
Randomisation and Masking 16 
Participant details were entered into the trial database, which automatically assigned 17 
participants with a valid measured BMI to one of the three interventions (brief 18 
intervention, referral to the commercial open-group behavioural weight loss programme 19 
(behavioural programme) for 12 weeks, or referral to the same programme for 52 20 
weeks) in a 2:5:5 allocation stratified by centre and gender, with a block size of 12. The 21 
randomisation sequence was generated by the trial statistician using Stata 12.1 and 22 
programmed into the database by the Data Manager. The sequence was unknown to 23 
research staff and participants. Once participants were enrolled and entered into the 24 
database, the database revealed the group allocation. Due to the nature of the 25 
intervention and the trial design, participants and research staff were not blinded to the 26 
intervention allocation after randomisation. 27 
Procedures 28 
Participants randomised to the behavioural programme were asked to attend a local 29 
Weight Watchers (WW) meeting once a week for the duration of their intervention (12 30 
weeks or 52 weeks). At their baseline visit they were given a list of local meeting times 31 
and locations, a voucher booklet for 12 visits (the expiry date was set for 14 weeks from 32 
baseline) and a unique code to access digital tools for the duration of their intervention. 33 
Meeting vouchers were identical to those used in the National Health Service (NHS) 34 
referral schemes operating elsewhere in the country and allowed participants to attend 35 
meetings without charge. At the meeting, they gave the voucher to the group leader, but 36 
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were asked not to mention their participation in the trial to the group leader or other 1 
members.  Participants in the 52-week programme group were given a further three 2 
books of vouchers when they returned for their 3 month visit (expiry date set for 54 3 
weeks from baseline).  4 
Participants allocated to the brief intervention were given a 32-page printed British Heart 5 
Foundation booklet of self-help weight management strategies10 and research staff read 6 
a scripted introduction that drew attention to each section of the booklet.  7 
All participants attended measurement appointments at 0, 3, 12, and 24 months. Height 8 
was measured to the nearest 0·1 cm using a stadiometer. Weight and fat mass were 9 
measured to the nearest 0·1 kg using a 4-point Tanita segmental body composition 10 
analyser. Waist circumference was measured to the nearest 0·1 cm using a tape 11 
measure, half way between the lowest rib and the iliac crest. Blood pressure was 12 
measured three times in a seated resting state using an automated blood pressure 13 
monitor, and the mean calculated. Biochemical measurements were optional. Willing 14 
participants were asked to give a fasting blood sample at 0 and 12 months for analysis 15 
of glucose, glycosylated haemoglobin (HbA1c) and lipid profile. All samples were analysed 16 
in Cambridge using standardised methods (web appendix).  17 
At each visit, participants self-reported their use of weight loss methods, including the 18 
allocated intervention, and completed the EQ5D-3L11,12 as a measure of quality of life. 19 
Data on health care resource use was also self-reported. Participants who were unable or 20 
unwilling to attend a 12 month visit (primary outcome measurement) were asked to 21 
provide a self-measured weight by phone or email. Self-reported weights are not 22 
included in the primary outcome analysis but are included in a sensitivity analysis (web 23 
appendix). 24 
Outcomes 25 
The primary outcome was change in body weight at 12 months. The secondary clinical 26 
outcomes were: body weight at 3 and 24 months; proportion of participants losing ≥5% 27 
body weight or ≥10% of baseline body weight at 3, 12 and 24 months; waist 28 
circumference, fat mass, and blood pressure at 3, 12 and 24 months; fasting blood 29 
glucose, HbA1c, triglycerides and HDL, LDL, and total cholesterol at 12 months; and self-30 
reported quality of life (EQ5D-3L) and health resource use at 3, 12 and 24 months. We 31 
did not anticipate that adverse events related to the interventions would occur and so 32 
did not formally record these. 33 
Statistical Analysis 34 
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The sample size was calculated based on data from our previous trials13,14 with an 1 
expected difference of 2·3 kg between the brief intervention and combined behavioural 2 
programme groups, 1·3 kg difference between 12-week and 52-week programmes, and 3 
an assumed standard deviation of 6 kg. The hierarchical-closed-testing procedure 4 
compared the behavioural programme arms with brief intervention using a one-sided 5 
test and then, only if significant at the 5% level, conducted a two-sided test for a 6 
difference between 12-week and 52-week programmes in order to preserve a type I 7 
error rate of 5% without the need for a multiplicity correction. With a sample of 1200 8 
participants allocated as 200 (brief intervention), 500 (12-week programme), and 500 9 
(52-week programme), we had 99·95% power to detect a difference of 2·3 kg between 10 
brief intervention and the behavioural programmes, and 92·87% power to detect a 11 
difference of 1·3 kg between 12-week and 52-week programmes. The overall power of 12 
the study was 92·82%. 13 
Analyses were pre-specified in the published protocol.9 The primary analyses evaluated 14 
differences between the intervention groups in mean weight change from baseline to 15 
12 months. Given levels of attrition commonly encountered in weight-loss trials, four 16 
analysis approaches were taken to account for the impact of missing data: a missing at 17 
random (MAR) analysis using a variance components model; a completers only analysis; 18 
baseline observation carried forward (BOCF); and last observation carried forward 19 
(LOCF).  For the MAR analysis, mean weight losses and their standard errors were 20 
obtained via a multiple imputation model using multivariate normal regression; 20 data 21 
sets for weight were imputed separately for each treatment group, with baseline weight, 22 
3-month weight, 12-month weight, and 24-month weight regressed on centre. A model 23 
for multivariate normal data with baseline weight, 3-month weight, 12-month weight, 24 
24-month weight as the outcome was fitted using measured weights at each time point 25 
via generalised least squares, with intervention group, visit, intervention group-by-visit 26 
interaction and centre included as fixed effects.  For the completers only, BOCF and 27 
LOCF analyses, fixed effect models for continuous normal data were fitted to the 12-28 
month weight data. The fixed effects were intervention group, centre and baseline 29 
weight.  Analyses of secondary outcomes were conducted using the same regression 30 
based models. Data reported in the body of the paper used the MAR assumption. The 31 
web appendix contains analyses by all four methods. Sensitivity analyses were 32 
conducted to examine whether findings were sensitive to timing of the 12-month 33 
assessment or the inclusion of self-reported weights. All analyses were conducted using 34 
Stata 13·1. 35 
A recent review highlighted the lack of evidence of this type of programme on socio-36 
economic inequalities4, so we also conducted a post-hoc analysis of potential interactions  37 
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between intervention effects and  gender, educational qualification and income. 1 
Coefficient estimates and their 95% confidence intervals were calculated for each fixed 2 
effect. 3 
To establish within-trial cost–effectiveness over 24 months, we calculated the 4 
incremental cost-effectiveness ratio (ICER) as incremental cost per additional kg weight 5 
loss (see web appendix for full details). If the participant attended at least one session, 6 
the NHS would be charged a flat rate of £48·50 (12-week programme) or £190 (52-week 7 
programme).  If they did not attend, there was no charge.  Non-intervention NHS costs 8 
were estimated from health resource use questionnaires, which were completed by 9 
participants at baseline, 3, 12, and 24 months and were framed within a three months 10 
recall period.15 To ascertain the full NHS costs incurred over the 24 months follow-up 11 
period we applied area under the curve methods.16 A secondary analysis examined the 12 
ICER over a 1-year time horizon, to enable comparability with similar studies with 13 
shorter follow up.  14 
We used the microsimulation model developed for the Foresight: Tackling Obesities 15 
project17,18 to estimate the effect of the three interventions on disease incidence, 16 
healthcare costs, quality adjusted life-years (QALY), and ICERs for 25 years following 17 
baseline (web appendix). This analysis used mean change in BMI for each intervention at 18 
1 and 2 years, and assumed that between 2 and 5 years all participants returned to their 19 
baseline weight in a linear manner (i.e. regained all weight lost) and then followed national 20 
trends based on data derived from repeated cross-sectional samples in the Health 21 
Survey for England.19  22 
The number of meetings attended by the participants in the behavioural programme 23 
groups between baseline and 3 months, 9 months and 12 months, and 21 months and 24 
24 months, was self-reported. The proportion of participants who self-reported utilising 25 
other weight loss interventions was also calculated.  26 
Data management was overseen by the coordinating centre’s data manager. The data 27 
set linking treatment group to participant outcomes was only released to the 28 
investigators following completion of data collection for the primary outcome. 29 
Role of the Funding Source 30 
The funders of the study had no role in the design, data collection, data analysis, data 31 
interpretation, or writing of the report. ALA and GMW had full access to all data and ALA 32 
had final responsibility for the decision to submit for publication.  33 
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RESULTS 1 
Between 18th October 2012 and 10th February 2014, 1954 participants were screened 2 
and 1269 were eligible and agreed to randomisation (Figure 1). Shortly after the 3 
baseline appointment, two enrolled participants were excluded because their GP reported 4 
illnesses that would have excluded them. These participants were removed and the 5 
remaining 1267 participants were included in the primary analyses. Data on participants 6 
who died during the trial is included up until the event. The number of participants 7 
completing each assessment was 1004 (79%) at 3 months, 823 (65%) at 12-months 8 
assessment, and 856 (68%) at 24-months. Using Pearson's chi-squared test, there was 9 
a borderline statistically significant association between the percentage of participants 10 
attending the 12-month appointment and intervention group (p=0.0475), though there 11 
was little evidence to suggest such an association for participants completing the 24-12 
month assessment (p=0.21). Examination of the effect of individual characteristics on 13 
attendance by intervention group found no statistical evidence of bias in attendance over 14 
the study’s duration. Analyses of biochemical risk factors are based on 837 participants 15 
(66%) who provided a blood sample at baseline. 16 
 17 
Table 1 shows baseline characteristics by intervention group. Participants had a mean 18 
BMI of 34·5 kg/m2 (SD 5·2), a mean age of 53·2 years (SD 13·8), 68% were female, 19 
90% were White, 15% had diabetes, 50% had hypertension. 20 
Figure 2 shows the weight trajectories of the three intervention groups at each time 21 
point using all measured weights. Mean (SE) weight change at 3 months was -2·04kg 22 
(0·30) following brief intervention, -4·84 kg (0·21) in the 12-week programme, and -23 
4·62 kg (0·18) in the 52-week programme. Participants in the combined behavioural 24 
programme arms lost more weight than those in the brief intervention [adjusted 25 
difference= -2·67 kg (95% CI -3·28, -2·07); p<0·0001] and there was no significant 26 
difference between the 12-week and 52-week programmes [adjusted difference=0·22 kg 27 
(95% CI -0·26, 0·69); p=0·371]. Mean weight change at 12 months, the primary 28 
outcome, was -3·26 kg (0·68) in brief intervention, -4·75 kg (0·35) in the 12-week 29 
programme, and -6·76 kg (0·42) in the 52-week programme (Table 2). Participants in 30 
the combined behavioural programme arms lost significantly more weight at 12 months 31 
than those receiving a brief intervention [adjusted difference=-2·71 kg (95% CI -3·86,-32 
1·55); p<0·0001] and participants in the 52-week programme lost significantly more 33 
weight than those in the 12-week programme [adjusted difference=-2·14 kg (95% CI -34 
3·05, -1·22); p<0·0001]. On average, participants in all groups regained weight between 35 
12 and 24 months but the differences between groups remained significant. Weight 36 
change between baseline and 24 months was -2·30 kg (0.73) in brief intervention, -3·00 37 
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kg (0.37) in the 12-week programme, and -4·29 kg (0·44) in the 52-week programme. 1 
Participants randomised to the behavioural programme lost significantly more weight 2 
than those receiving a brief intervention [adjusted difference = -1·44 kg (95% CI -2·87,-3 
0·00); p=0·0247]. Participants randomised to the 52-week programme lost significantly 4 
more weight than those receiving the 12-week programme [adjusted difference = -1·32 5 
kg (95% CI -2·46,-0·18); p=0·0231].  6 
Participants randomised to the 12-week programme lost significantly more weight than 7 
the brief intervention group at 3 months [adjusted difference=-2·79kg (-3·44,-2·13); 8 
p<0·0001] and 12 months [adjusted difference=-1·61kg (-2·84, -0·38); p=0·0105] but 9 
there was no significant difference in weight loss between these groups at 24 months 10 
[adjusted difference = -0·74 kg (95% CI -2·45, 0·77); p=0·338]. 11 
Sensitivity analyses examining weight change with alternative assumptions about 12 
missing data gave similar results (web appendix).  Research centre was not a significant 13 
predictor of weight change in any of the models. There was no evidence suggestion that 14 
the intervention effect differed by participant gender (p=0·48), educational attainment 15 
(p=0·79), or household income (p=0·64).   16 
The percentage of participants losing ≥5% and ≥10% weight, and the relative risk 17 
between groups is shown in Table 3. At 12-month follow up, 57% of participants in the 18 
52-week programme had lost ≥5% of weight, compared with 42% in the 12-week 19 
programme and 25% in the brief intervention. Participants in the behavioural 20 
programme were significantly more likely than the brief intervention group to lose ≥5% 21 
and ≥10% body weight. Participants in the 52-week programme were significantly more 22 
likely than those in the 12-week programme to lose ≥5% and ≥10% weight.  23 
At 12 and 24 months, participants in the 52-week programme had greater reductions in 24 
waist and fat mass than participants in the 12-week programme or brief intervention 25 
group (Table 4). At 12 months, participants in the 52-week programme had greater 26 
reductions in HbA1c than those in the 12-week programme [adjusted difference=-1·31 27 
mmol/mol (95% CI -2·47, -0·15); p=0·0268] and brief intervention [adjusted 28 
difference=-2·65 mmol/mol (95% CI -4·28, -1·01); p=0·0015] and greater reductions in 29 
fasting plasma glucose than those in the 12-week programme [adjusted difference=-30 
0·29 mmol/L (95% CI -0·58, -0·00); p=0·0497] and brief intervention [adjusted 31 
difference=-0·46 mmol/L (95% CI -0·88,-0·03); p=0·0342]. There were no significant 32 
differences between the 12-week programme and brief intervention for either HbA1c or 33 
fasting glucose. Changes over time in blood pressure, quality of life, triglycerides and 34 
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HDL, LDL and total cholesterol were small and there were no significant differences 1 
between groups. No participants reported adverse events related to the intervention. 2 
 3 
Intervention usage is summarised in Table 5. At 3 months, 5% participants in the brief 4 
intervention group had attended a commercial weight management programme, 5 
compared with 68% in the 12-week programme and 69% in the 52-week programme. 6 
Only 1% of participants in all groups attended an NHS-led programme and less than 1% 7 
used weight-loss medication. For participants referred to the behavioural programmes, 8 
the mean number of sessions attended was 8.4 (SD 4.2) in the 12-week programme and 9 
28.2 (SD 14.8) in the 52-week programme.  Full details of the economic evaluation are 10 
in the web appendix. In brief, intervention costs, including GP referral time, are 11 
estimated as £18.50 (brief intervention), £60 (12-week programme) and £195 (52-week 12 
programme).  There were no significant differences between groups in health care 13 
resource use per participant at baseline and throughout follow-up. The estimated 14 
incremental NHS cost per additional kg weight loss (expressed here as £/kg) was £91/kg 15 
for the 12-week programme  and £159/kg for the 52-week programme.  Analysis using a 16 
1-year time horizon for consistency with other studies, reduced the ICER to £26/kg and 17 
£75/kg respectively. 18 
The cost-effectiveness acceptability curve (CEAC, web appendix Figure A2) is based on 19 
weight loss at 2 years and includes all NHS costs incurred during that time.  If decision-20 
makers are willing to pay at least £60/kg, then the 12-week programme would be the 21 
preferred strategy.  If decision-makers are willing to pay £200/kg, then the 52-week is 22 
the preferred strategy. If costs are restricted to intervention-only costs, the 52-week 23 
programme becomes the preferred strategy at £100/kg.  24 
Microsimulation modelling estimated that over 25 years after the baseline year, the 12-25 
week programme was cost-saving (dominant) compared with the brief intervention. The 26 
52-week programme was cost-effective relative to both the brief intervention (ICER = 27 
£2498/QALY) and the 12-week programme (£3804/QALY).  28 
In comparison to the brief intervention, the 12-week programme resulted in 623 fewer 29 
incident cases of disease, 643 additional QALYs, and a cost-saving of approximately 30 
£68,000 per 100,000 individuals. In comparison to the 12-week programme, the 52-31 
week programme resulted in 1786 fewer incident cases of disease and generated 1282 32 
additional QALYS, at a cost of approximately £4·9 million per 100,000 individuals. 33 
Further details are included in the web appendix.  34 
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DISCUSSION 1 
Adults in primary care with overweight or obesity who were referred to an open-group 2 
behavioural weight management programme lost 2·7 kg  (±1.2) more weight at 1-year 3 
follow up than those who were given brief advice and self-help materials. Those who 4 
were referred to this behavioural programme for 52-weeks lost 2·1 kg (±0.9) more 5 
weight than those who were referred for 12 weeks. Fifty-seven percent of participants 6 
referred to the 52-week programme lost more than 5% weight, compared with 42% 7 
referred to the 12-week programme and 25% of those in the brief intervention group. 8 
Five percent is often used as a cut-off for clinically significant weight loss, although even 9 
smaller weight losses are associated with improvements in markers of cardiovascular 10 
disease risk.20 On average all groups regained some of the weight lost and at 2-years the 11 
difference in weight loss between the 12-week programme and the brief intervention 12 
was no longer significant, whereas the weight loss in the 52-week programme was 13 
significantly greater than both other groups. Participants in the 52-week programme also 14 
had larger reductions in waist circumference, fat mass, fasting glucose and HbA1c than 15 
participants in the 12-week programme and the brief intervention. When the impact of 16 
the 12-week programme was modelled over 25 years, it was cost-saving compared with 17 
the brief intervention. Although the 52-week programme was more expensive in the 18 
within-trial analysis, when the impact was modelled over 25 years, it resulted in the 19 
greatest gain in QALYs and the greatest reduction in disease incidence. By standards set 20 
by the National Institute of Health and Care Excellence, the intervention is cost-effective 21 
in comparison to both the brief intervention and the 12-week programme. It should be 22 
noted that this assessment of cost-effectiveness does not include potential further 23 
savings in social care and indirect healthcare costs. It also uses a flat rate cost for each 24 
intervention, when in practice full costs would not be incurred if people did not complete 25 
the course, thus potentially overestimating intervention costs. 26 
A strength of this trial is the large patient group that is broadly generalisable to the UK 27 
population. In our previous trial13, participants with a BMI 27-35 kg/m2 were identified 28 
during routine consultations and recruited to the trial.  The current trial was more 29 
inclusive (BMI 28-68 kg/m2) and participants were recruited by letter based on weight 30 
records. In the former, the mean BMI was 31·4 kg/m2 whereas in the present study 31 
participants had a mean BMI of 34·5 kg/m2, more comparable to the population typically 32 
referred to open-group behavioural programmes in NHS referral schemes.21 Mailing 33 
invitations to all eligible patients resulted in a higher proportion of male participants than 34 
seen in routine referral schemes,13,21 although this is still lower than the proportion of 35 
males in the UK population.22 More than half of participating practices were from areas 36 
with an index of multiple deprivation that is higher (more deprived) than the national 37 
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median and participants were drawn from a wide range of socioeconomic groups.23  Most 1 
participants were white, with the proportion enrolled reflecting the ethnic make-up of the 2 
UK.22 There was no evidence that the intervention effects varied by gender or socio-3 
economic status.  This is striking given oft-repeated views that these interventions are 4 
not appropriate for men and concerns that individual behavioural interventions 5 
exacerbate socio-economic inequalities in health.24 25 Taken together, the findings 6 
suggest that the intervention effects reported here may be generalisable to the UK adult 7 
population.  Although uptake of the programmes by more deprived populations is 8 
somewhat lower than in less deprived areas23, more targeted schemes, as have been 9 
implemented elsewhere14, might reduce health inequalities.  10 
 11 
Loss to follow up at 1 year was slightly below average for weight loss trials,26 and there 12 
was little attrition between 1 and 2 years. Three different intention-to-treat analyses 13 
were conducted that each make different assumptions about missing data, as well as two 14 
sensitivity analyses. The consistency of effects demonstrates the robustness of our 15 
findings. The pragmatic nature of the trial meant that participants in all groups were free 16 
to use other weight-loss methods during the trial. This reflects how these interventions 17 
are routinely delivered and allows direct translation of these findings to clinical practice. 18 
Only a tiny minority of participants in each arm used other NHS interventions or weight-19 
loss medications, and only a small proportion of participants who were assigned to the 20 
brief intervention group went on to use a commercial weight loss programme. A strength 21 
of this trial is the 2-year follow up of participants, which gives important information on 22 
weight trajectories after treatment ends. The modelled cost-effectiveness over 25 years 23 
is based on assumptions about weight trajectories beyond 2 years, however we have 24 
been relatively conservative in these assumptions, assuming all weight lost is regained 25 
within 5 years. The within-trial ICERs are strongly affected by non-significant differences 26 
between groups in healthcare costs (highest in the 52-week programme and lowest in 27 
the 12-week programme) based on health-care usage data in 46.7% participants. 28 
However, sensitivity analyses (web appendix) provide information with which to assess 29 
the strength of these findings. Fasting status when blood was taken and attendance at 30 
Weight Watchers were self-reported and could be susceptible to reporting/recall bias.   31 
Reliance on subjects confirming that the blood sample was taken in a fasting state is a 32 
universal concern in any free-living study and findings related to glucose were congruent 33 
with findings for HbA1c, which is not affected by fasting status. Attendance at Weight 34 
Watchers was self-reported and could be susceptible to reporting/recall bias. However, 35 
any bias in the attendance data does not impact the pre-specified outcomes which were 36 
conducted on an intention-to treat basis. 37 
 38 
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The weight losses seen in this study are consistent with previous trials of 12 weeks and 1 
52 weeks referral to commercial open-group behavioural weight management 2 
programmes, suggesting findings are robust.13,14,27 Estimates of the mean incremental 3 
cost per additional kg lost for either duration of treatment are within the range of other 4 
behavioural programmes (web appendix Table A4). The reductions in fasting glucose and 5 
HbA1c were not seen in our previous trial of the 52-week programme,
28 perhaps because 6 
the lower baseline BMI and stricter inclusion criteria in that study meant that participants 7 
had lower baseline values. Almost half of participants in the current trial had elevated 8 
fasting glucose and/or HbA1c at baseline. Reductions seen in the 52-week programme 9 
participants at 12 months (-0·5 mmol/l fasting glucose and –2·8 mmol/mol HbA1c) are 10 
larger than those seen at the same timepoint in the intensive lifestyle intervention arm 11 
of the Diabetes Prevention Programme (DPP; approximately -0·4 mmol/l fasting glucose 12 
and  -1 mmol/mol HbA1c)
29, whose participants were similar to those in the current study 13 
in baseline BMI, HbA1c and glucose and had similar weight loss at 12 months, but 14 
achieved at a fraction of the cost.30 Notwithstanding gradual weight regain and increase 15 
in associated risk factors observed over 15 years follow-up, DPP achieved a 27% 16 
reduction in the cumulative incidence of diabetes in the lifestyle intervention relative to 17 
the control group.31 However the impact of these more scalable interventions on 18 
diabetes incidence will depend on whether longer term weight trajectories are similar.  19 
The programme we evaluated is widely available and participants in the brief 20 
intervention group were neither encouraged nor discouraged from attending other 21 
weight loss programmes. Only 1 in 20 chose to do so, compared with 14 in 20 of those 22 
referred to these programmes. In the 12 week group, 19% of participants were still 23 
attending the programme 12 months later at their own cost, compared with 9% of those 24 
in the brief intervention. This suggests some legacy effect of the initial referral. However, 25 
this is lower than the 42% of participants in the 52-week group who were still attending 26 
at 12 months. As the median household income was about £30,000, it is likely that 27 
many people would have been able to pay the cost of the programme (approximately 28 
£5/week) suggesting it may be the act of referral itself that is the source of motivation 29 
to attend, though it is impossible to exclude that lower attendance in other groups was 30 
related to the cost. The importance of the referral is supported by qualitative data that 31 
found the GP referral is perceived as an implicit recommendation of the programme and 32 
the allocation of NHS resources to enabling their attendance increases motivation to 33 
attend.32  It is also supported by another trial among people with obesity attending a GP 34 
consultation unrelated to their weight, where 77% who agreed to participate in the trial 35 
and were offered a referral to a weight management programme accepted it and 40% 36 
attended.33  37 
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The absolute weight loss among participants receiving only the brief intervention 1 
warrants consideration. Participants given 5 minutes of non-tailored advice and a self-2 
help booklet lost over 3 kg at 12 months and over 2 kg at 24 months. Weight change in 3 
this group is larger than the average weight loss observed in a recent meta-analysis3 for 4 
interventions led by generalist primary care teams, and larger than the average weight 5 
loss seen in a systematic review of self-help interventions.34 Given the small cost of this 6 
intervention (self-help booklet and three short appointments that could be delivered by a 7 
nurse or health care assistant), observational data would support the implementation of 8 
this intervention as a minimal standard in primary care. However, this finding highlights 9 
the importance of including a control group when evaluating weight loss interventions. A 10 
recent review has shown that control groups given minimal interventions will generally 11 
lose weight over the course of a trial.35 In this review there was considerable 12 
heterogeneity in the absolute weight loss of control groups, which may reflect differences 13 
in study populations and trial design. The current trial illustrates this showing 3·4 kg 14 
weight loss in a minimal contact control group, when an almost identical brief 15 
intervention achieved less than 1 kg weight loss when used as a control group in a 16 
different population and context.36 17 
This trial demonstrates that referral to this commercial open-group behavioural weight 18 
loss programme increases weight loss relative to a brief intervention in primary care. 19 
Increasing the duration of the programme from 12 weeks to 52 weeks increases weight 20 
loss and improvements in other markers of diabetes and cardiovascular risk, most 21 
notably glycosylated haemoglobin and fasting glucose. Economic evaluation of this trial 22 
found that while the 52-week programme requires greater initial investment, it is cost-23 
effective in the longer-term and commissioners should consider a move towards 24 
extended referral schemes. 25 
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Research in context panel 1 
Evidence before this study  2 
A systematic review and meta-analysis conducted in November 2012 synthesised data 3 
from 37 trials of behavioural weight management programmes delivered in a context 4 
that could be replicated in routine clinical practice. Three studies evaluated primary care 5 
referral to a commercial open-group programme in comparison to a control group and 6 
pooled results found a mean difference of 2.22 kg in favour of the intervention group, 7 
but no consistent effects on markers of cardiovascular risk. The quality of the evidence 8 
was assessed as moderate. These interventions lasted 12, 52, and 104 weeks with no 9 
studies comparing effectiveness with different durations of treatment. Indirect 10 
comparisons across all 37 studies found no effect of duration of intervention on weight 11 
loss at 12 months. However, a previous systematic review and meta-analysis of direct 12 
comparisons between interventions of different lengths, mostly from controlled research 13 
studies, found that interventions providing ‘extended care’ led to 3·2 kg less weight 14 
regain than control interventions over a mean follow up period of 17·6 months following 15 
initial weight loss. An updated search of Pub Med and Scopus (to 12th January 2017) 16 
found no new direct comparisons of treatment duration. 17 
Added value of this study  18 
In a large randomised controlled trial in a sample broadly generalisable to the UK 19 
population, this trial finds that referral to a commercial programme for 12 weeks or 52 20 
weeks produces greater weight loss than a brief self-help intervention. It extends 21 
previous findings by demonstrating that referral for 52 weeks achieves significantly 22 
greater weight loss than the standard 12-week referrals currently used in the UK 23 
National Health Service over 2 years. Contrary to common criticisms that these 24 
interventions could exacerbate health inequalities, there was no evidence that the 25 
outcome of treatment is moderated by socioeconomic factors such as gender, education 26 
and income.We also show, for the first time, that this extended referral achieves 27 
improvements in fasting glucose and glycosylated haemoglobin equivalent to more 28 
intensive health professional-led interventions. Using microsimulation modelling, we 29 
show for the first time that over a 25-year period the 12-week programme is cost-saving 30 
compared with a brief intervention, and that the 52-week programme is cost-effective 31 
compared with the 12-week programme.  32 
Implications of all the available evidence 33 
Referral to a commercial open-group behavioural weight loss programme for 12 weeks is 34 
an effective weight loss intervention and could be cost-saving for adults in the general 35 
population in the long term. Extending the referral length from 12 weeks (UK standard) 36 
to 52 weeks would significantly increase the clinical effectiveness of these programmes, 37 
by achieving greater weight loss and reductions in risk factors for diabetes and 38 
cardiovascular disease. While the 52-week programme is more expensive in the short 39 
term, in the longer term it would likely be cost-effective because of greater reductions in 40 
disease incidence. 41 
 42 
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Summary  1 
Background 2 
There is good evidence that primary care referral to an open-group behavioural 3 
programme is an effective treatment for obesity, but little evidence on optimal treatment 4 
duration.  5 
Methods 6 
In this non-blinded parallel-group randomised controlled trial, we recruited participants 7 
(age ≥18 years, BMI ≥28 kg/m²) through 23 primary care practices in England. 8 
Participants were randomised using the study database in a 2:5:5 allocation to: brief 9 
weight loss intervention, a weight management programme (Weight Watchers®) for 12 10 
weeks, or the same weight management programme for 52-weeks. We followed 11 
participants over two years. The primary outcome was weight at one year, analysed 12 
using mixed-effects models according to intention-to-treat principles adjusted for centre 13 
and baseline weight. In a hierarchical-closed-testing procedure we compared combined 14 
behavioural programme arms with brief intervention, then compared the 12-week and 15 
52-week programmes. We conducted a within-trial cost–effectiveness analysis using 16 
person-level data and modelled outcomes over a 25-year horizon using microsimulation. 17 
Current Controlled Trials ISRCTN82857232.  18 
 19 
Findings 20 
Between 18th October 2012 and 10th February 2014, 1267 eligible participants were 21 
randomised to the brief intervention (211), 12-week programme (528) and 52-week 22 
programme (528). 823 (65%) completed an assessment at one year and 856 (68%) at 23 
two years. All participants were included in the analyses. At one year, mean weight 24 
change was -3·26 kg (brief intervention), -4·75 kg (12-week programme), and -6·76 kg 25 
(52-week programme). Participants in the behavioural programme lost more weight than 26 
those in the brief intervention [adjusted difference = -2·71 kg (95% CI -3·86,-1·55); 27 
p<0·0001]. The 52-week programme was more effective than the 12-week programme 28 
[adjusted difference= -2·14 kg (95% CI -3·05, -1·22); p<0·0001]. Differences between 29 
groups were still significant at two years. No adverse events related to the intervention 30 
were reported. Over two years, the incremental cost-effectiveness ratio (ICER;compared 31 
with brief intervention) was £159/kg lost for the 52-week programme and £91/kg for the 32 
12-week programme. Modelled over 25 years after baseline, the ICER for the 12-week 33 
programme was dominant compared with the brief intervention. The ICER for the 52-34 
week programme was cost-effective compared with the brief intervention (£2498/QALY) 35 
and the 12-week programme (£3804/QALY).  36 
Interpretation 37 
For adults with overweight or obesity, referral to this open-group behavioural weight loss 38 
programme for at least 12 weeks is more effective than brief advice and self-help 39 
materials. A 52-week programme produces greater weight loss and other clinical benefits 40 
than a 12-week programme and, although it costs more, modelling suggests it is cost-41 
effective in the longer term. 42 
 43 
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BACKGROUND 1 
The burden of disease attributable to excess weight places considerable strain on health 2 
care resources across the world.1,2 Behavioural weight management programmes are the 3 
first-line treatment for overweight and obesity, and although there is good evidence that 4 
some of these programmes can be effective, others are not.3 This may be due to 5 
differences in content and format of interventions, including the length of time support is 6 
provided. In the UK, the National Institute for Health and Care Excellence (NICE) public 7 
health guidance recommends that behavioural weight management programmes should 8 
last a minimum of 12 weeks4 and this is the standard length of the most commonly 9 
commissioned interventions.5 However, there is conflicting evidence about whether 10 
longer treatment duration would be more effective. 6,7 11 
Open-group behavioural weight loss programmes are among the most commonly 12 
commissioned programmes in the UK and evidence suggests these programmes are 13 
effective and cost-effective.3,8  The current trial was designed to directly compare 14 
whether 52-week referral to an open-group weight management programme would 15 
achieve significantly greater weight loss and improvements in a range of secondary 16 
health outcomes than the current practice of 12-week referrals, and be more cost-17 
effective.  18 
METHODS 19 
Study Design 20 
This was a multi-centre, non-blinded, multi-arm parallel groups randomised controlled 21 
trial with imbalanced randomisation (2:5:5), conducted in England. The full protocol is 22 
described elsewhere.9 23 
In brief, participants were recruited from 23 primary care practices across England 24 
between October 2012 and February 2014. Recruitment and follow up was conducted by 25 
three research centres: MRC Human Nutrition Research, Cambridge (coordinating 26 
centre), the University of Liverpool, and the University of Oxford. Cambridge and 27 
Liverpool teams recruited local practices and research staff conducted study visits at the 28 
research centre. Oxford recruited practices across southern and eastern England and 29 
practice staff (usually a research nurse) conducted study visits at the practice.  30 
Ethical approval was received from NRES Committee East of England (12/EE/0363). This 31 
trial was registered at Current Controlled Trials ISRCTN85485463 on 12th October 2012.  32 
Participants 33 
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Eligible participants (aged ≥18years; body mass index (BMI) ≥28 kg/m²) were identified 1 
through practice records. Exclusion criteria were: planned (within two years) or current 2 
pregnancy; previous or planned bariatric surgery; currently following a structured, 3 
monitored weight-loss programme; participating in other research that could confound 4 
outcome measures; eating disorder; non-English speaking or with special communication 5 
needs. Practices could exclude additional patients they felt it was inappropriate to invite 6 
but were asked to report reasons. These additional exclusions included terminal 7 
illness/palliative care, dementia, a severe mental health problem or learning difficulty, 8 
carer for a terminally ill relative, or recently bereaved. Patients were invited by letter and 9 
asked to contact the local study coordinator for telephone screening if they were 10 
interested in participating. Eligible and willing participants were given an appointment, 11 
where a member of the research team weighed them and measured their height to 12 
confirm eligibility before randomisation. Where more than one household member was 13 
eligible and interested in participating, the first to enrol was taken as the participant. All 14 
participants gave written informed consent.  15 
Randomisation and Masking 16 
Participant details were entered into the trial database, which automatically assigned 17 
participants with a valid measured BMI to one of the three interventions (brief 18 
intervention, referral to the commercial open-group behavioural weight loss programme 19 
(behavioural programme) for 12 weeks, or referral to the same programme for 52 20 
weeks) in a 2:5:5 allocation stratified by centre and gender, with a block size of 12. The 21 
randomisation sequence was generated by the trial statistician using Stata 12.1 and 22 
programmed into the database by the Data Manager. The sequence was unknown to 23 
research staff and participants. Once participants were enrolled and entered into the 24 
database, the database revealed the group allocation. Due to the nature of the 25 
intervention and the trial design, participants and research staff were not blinded to the 26 
intervention allocation after randomisation. 27 
Procedures 28 
Participants randomised to the behavioural programme were asked to attend a local 29 
Weight Watchers (WW) meeting once a week for the duration of their intervention (12 30 
weeks or 52 weeks). At their baseline visit they were given a list of local meeting times 31 
and locations, a voucher booklet for 12 visits (the expiry date was set for 14 weeks from 32 
baseline) and a unique code to access digital tools for the duration of their intervention. 33 
Meeting vouchers were identical to those used in the National Health Service (NHS) 34 
referral schemes operating elsewhere in the country and allowed participants to attend 35 
meetings without charge. At the meeting, they gave the voucher to the group leader, but 36 
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were asked not to mention their participation in the trial to the group leader or other 1 
members.  Participants in the 52-week programme group were given a further three 2 
books of vouchers when they returned for their 3 month visit (expiry date set for 54 3 
weeks from baseline).  4 
Participants allocated to the brief intervention were given a 32-page printed British Heart 5 
Foundation booklet of self-help weight management strategies10 and research staff read 6 
a scripted introduction that drew attention to each section of the booklet.  7 
All participants attended measurement appointments at 0, 3, 12, and 24 months. Height 8 
was measured to the nearest 0·1 cm using a stadiometer. Weight and fat mass were 9 
measured to the nearest 0·1 kg using a 4-point Tanita segmental body composition 10 
analyser. Waist circumference was measured to the nearest 0·1 cm using a tape 11 
measure, half way between the lowest rib and the iliac crest. Blood pressure was 12 
measured three times in a seated resting state using an automated blood pressure 13 
monitor, and the mean calculated. Biochemical measurements were optional. Willing 14 
participants were asked to give a fasting blood sample at 0 and 12 months for analysis 15 
of glucose, glycosylated haemoglobin (HbA1c) and lipid profile. All samples were analysed 16 
in Cambridge using standardised methods (web appendix).  17 
At each visit, participants self-reported their use of weight loss methods, including the 18 
allocated intervention, and completed the EQ5D-3L11,12 as a measure of quality of life. 19 
Data on health care resource use was also self-reported. Participants who were unable or 20 
unwilling to attend a 12 month visit (primary outcome measurement) were asked to 21 
provide a self-measured weight by phone or email. Self-reported weights are not 22 
included in the primary outcome analysis but are included in a sensitivity analysis (web 23 
appendix). 24 
Outcomes 25 
The primary outcome was change in body weight at 12 months. The secondary clinical 26 
outcomes were: body weight at 3 and 24 months; proportion of participants losing ≥5% 27 
body weight or ≥10% of baseline body weight at 3, 12 and 24 months; waist 28 
circumference, fat mass, and blood pressure at 3, 12 and 24 months; fasting blood 29 
glucose, HbA1c, triglycerides and HDL, LDL, and total cholesterol at 12 months; and self-30 
reported quality of life (EQ5D-3L) and health resource use at 3, 12 and 24 months. We 31 
did not anticipate that adverse events related to the interventions would occur and so 32 
did not formally record these. 33 
Statistical Analysis 34 
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The sample size was calculated based on data from our previous trials13,14 with an 1 
expected difference of 2·3 kg between the brief intervention and combined behavioural 2 
programme groups, 1·3 kg difference between 12-week and 52-week programmes, and 3 
an assumed standard deviation of 6 kg. The hierarchical-closed-testing procedure 4 
compared the behavioural programme arms with brief intervention using a one-sided 5 
test and then, only if significant at the 5% level, conducted a two-sided test for a 6 
difference between 12-week and 52-week programmes in order to preserve a type I 7 
error rate of 5% without the need for a multiplicity correction. With a sample of 1200 8 
participants allocated as 200 (brief intervention), 500 (12-week programme), and 500 9 
(52-week programme), we had 99·95% power to detect a difference of 2·3 kg between 10 
brief intervention and the behavioural programmes, and 92·87% power to detect a 11 
difference of 1·3 kg between 12-week and 52-week programmes. The overall power of 12 
the study was 92·82%. 13 
Analyses were pre-specified in the published protocol.9 The primary analyses evaluated 14 
differences between the intervention groups in mean weight change from baseline to 15 
12 months. Given levels of attrition commonly encountered in weight-loss trials, four 16 
analysis approaches were taken to account for the impact of missing data: a missing at 17 
random (MAR) analysis using a variance components model; a completers only analysis; 18 
baseline observation carried forward (BOCF); and last observation carried forward 19 
(LOCF).  For the MAR analysis, mean weight losses and their standard errors were 20 
obtained via a multiple imputation model using multivariate normal regression; 20 data 21 
sets for weight were imputed separately for each treatment group, with baseline weight, 22 
3-month weight, 12-month weight, and 24-month weight regressed on centre. A model 23 
for multivariate normal data with baseline weight, 3-month weight, 12-month weight, 24 
24-month weight as the outcome was fitted using measured weights at each time point 25 
via generalised least squares, with intervention group, visit, intervention group-by-visit 26 
interaction and centre included as fixed effects.  For the completers only, BOCF and 27 
LOCF analyses, fixed effect models for continuous normal data were fitted to the 12-28 
month weight data. The fixed effects were intervention group, centre and baseline 29 
weight.  Analyses of secondary outcomes were conducted using the same regression 30 
based models. Data reported in the body of the paper used the MAR assumption. The 31 
web appendix contains analyses by all four methods. Sensitivity analyses were 32 
conducted to examine whether findings were sensitive to timing of the 12-month 33 
assessment or the inclusion of self-reported weights. All analyses were conducted using 34 
Stata 13·1. 35 
A recent review highlighted the lack of evidence of this type of programme on socio-36 
economic inequalities4, so we also conducted a post-hoc analysis of potential interactions  37 
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between intervention effects and  gender, educational qualification and income. 1 
Coefficient estimates and their 95% confidence intervals were calculated for each fixed 2 
effect. 3 
To establish within-trial cost–effectiveness over 24 months, we calculated the 4 
incremental cost-effectiveness ratio (ICER) as incremental cost per additional kg weight 5 
loss (see web appendix for full details). If the participant attended at least one session, 6 
the NHS would be charged a flat rate of £48·50 (12-week programme) or £190 (52-week 7 
programme).  If they did not attend, there was no charge.  Non-intervention NHS costs 8 
were estimated from health resource use questionnaires, which were completed by 9 
participants at baseline, 3, 12, and 24 months and were framed within a three months 10 
recall period.15 To ascertain the full NHS costs incurred over the 24 months follow-up 11 
period we applied area under the curve methods.16 A secondary analysis examined the 12 
ICER over a 1-year time horizon, to enable comparability with similar studies with 13 
shorter follow up.  14 
We used the microsimulation model developed for the Foresight: Tackling Obesities 15 
project17,18 to estimate the effect of the three interventions on disease incidence, 16 
healthcare costs, quality adjusted life-years (QALY), and ICERs for 25 years following 17 
baseline (web appendix). This analysis used mean change in BMI for each intervention at 18 
1 and 2 years, and assumed that between 2 and 5 years all participants returned to their 19 
baseline weight in a linear manner (i.e. regained all weight lost) and then followed national 20 
trends based on data derived from repeated cross-sectional samples in the Health 21 
Survey for England.19  22 
The number of meetings attended by the participants in the behavioural programme 23 
groups between baseline and 3 months, 9 months and 12 months, and 21 months and 24 
24 months, was self-reported. The proportion of participants who self-reported utilising 25 
other weight loss interventions was also calculated.  26 
Data management was overseen by the coordinating centre’s data manager. The data 27 
set linking treatment group to participant outcomes was only released to the 28 
investigators following completion of data collection for the primary outcome. 29 
Role of the Funding Source 30 
The funders of the study had no role in the design, data collection, data analysis, data 31 
interpretation, or writing of the report. ALA and GMW had full access to all data and ALA 32 
had final responsibility for the decision to submit for publication.  33 
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RESULTS 1 
Between 18th October 2012 and 10th February 2014, 1954 participants were screened 2 
and 1269 were eligible and agreed to randomisation (Figure 1). Shortly after the 3 
baseline appointment, two enrolled participants were excluded because their GP reported 4 
illnesses that would have excluded them. These participants were removed and the 5 
remaining 1267 participants were included in the primary analyses. Data on participants 6 
who died during the trial is included up until the event. The number of participants 7 
completing each assessment was 1004 (79%) at 3 months, 823 (65%) at 12-months 8 
assessment, and 856 (68%) at 24-months. Using Pearson's chi-squared test, there was 9 
a borderline statistically significant association between the percentage of participants 10 
attending the 12-month appointment and intervention group (p=0.0475), though there 11 
was little evidence to suggest such an association for participants completing the 24-12 
month assessment (p=0.21). Examination of the effect of individual characteristics on 13 
attendance by intervention group found no statistical evidence of bias in attendance over 14 
the study’s duration. Analyses of biochemical risk factors are based on 837 participants 15 
(66%) who provided a blood sample at baseline. 16 
 17 
Table 1 shows baseline characteristics by intervention group. Participants had a mean 18 
BMI of 34·5 kg/m2 (SD 5·2), a mean age of 53·2 years (SD 13·8), 68% were female, 19 
90% were White, 15% had diabetes, 50% had hypertension. 20 
Figure 2 shows the weight trajectories of the three intervention groups at each time 21 
point using all measured weights. Mean (SE) weight change at 3 months was -2·04kg 22 
(0·30) following brief intervention, -4·84 kg (0·21) in the 12-week programme, and -23 
4·62 kg (0·18) in the 52-week programme. Participants in the combined behavioural 24 
programme arms lost more weight than those in the brief intervention [adjusted 25 
difference= -2·67 kg (95% CI -3·28, -2·07); p<0·0001] and there was no significant 26 
difference between the 12-week and 52-week programmes [adjusted difference=0·22 kg 27 
(95% CI -0·26, 0·69); p=0·371]. Mean weight change at 12 months, the primary 28 
outcome, was -3·26 kg (0·68) in brief intervention, -4·75 kg (0·35) in the 12-week 29 
programme, and -6·76 kg (0·42) in the 52-week programme (Table 2). Participants in 30 
the combined behavioural programme arms lost significantly more weight at 12 months 31 
than those receiving a brief intervention [adjusted difference=-2·71 kg (95% CI -3·86,-32 
1·55); p<0·0001] and participants in the 52-week programme lost significantly more 33 
weight than those in the 12-week programme [adjusted difference=-2·14 kg (95% CI -34 
3·05, -1·22); p<0·0001]. On average, participants in all groups regained weight between 35 
12 and 24 months but the differences between groups remained significant. Weight 36 
change between baseline and 24 months was -2·30 kg (0.73) in brief intervention, -3·00 37 
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kg (0.37) in the 12-week programme, and -4·29 kg (0·44) in the 52-week programme. 1 
Participants randomised to the behavioural programme lost significantly more weight 2 
than those receiving a brief intervention [adjusted difference = -1·44 kg (95% CI -2·87,-3 
0·00); p=0·0247]. Participants randomised to the 52-week programme lost significantly 4 
more weight than those receiving the 12-week programme [adjusted difference = -1·32 5 
kg (95% CI -2·46,-0·18); p=0·0231].  6 
Participants randomised to the 12-week programme lost significantly more weight than 7 
the brief intervention group at 3 months [adjusted difference=-2·79kg (-3·44,-2·13); 8 
p<0·0001] and 12 months [adjusted difference=-1·61kg (-2·84, -0·38); p=0·0105] but 9 
there was no significant difference in weight loss between these groups at 24 months 10 
[adjusted difference = -0·74 kg (95% CI -2·45, 0·77); p=0·338]. 11 
Sensitivity analyses examining weight change with alternative assumptions about 12 
missing data gave similar results (web appendix).  Research centre was not a significant 13 
predictor of weight change in any of the models. There was no evidence suggestion that 14 
the intervention effect differed by participant gender (p=0·48), educational attainment 15 
(p=0·79), or household income (p=0·64).   16 
The percentage of participants losing ≥5% and ≥10% weight, and the relative risk 17 
between groups is shown in Table 3. At 12-month follow up, 57% of participants in the 18 
52-week programme had lost ≥5% of weight, compared with 42% in the 12-week 19 
programme and 25% in the brief intervention. Participants in the behavioural 20 
programme were significantly more likely than the brief intervention group to lose ≥5% 21 
and ≥10% body weight. Participants in the 52-week programme were significantly more 22 
likely than those in the 12-week programme to lose ≥5% and ≥10% weight.  23 
At 12 and 24 months, participants in the 52-week programme had greater reductions in 24 
waist and fat mass than participants in the 12-week programme or brief intervention 25 
group (Table 4). At 12 months, participants in the 52-week programme had greater 26 
reductions in HbA1c than those in the 12-week programme [adjusted difference=-1·31 27 
mmol/mol (95% CI -2·47, -0·15); p=0·0268] and brief intervention [adjusted 28 
difference=-2·65 mmol/mol (95% CI -4·28, -1·01); p=0·0015] and greater reductions in 29 
fasting plasma glucose than those in the 12-week programme [adjusted difference=-30 
0·29 mmol/L (95% CI -0·58, -0·00); p=0·0497] and brief intervention [adjusted 31 
difference=-0·46 mmol/L (95% CI -0·88,-0·03); p=0·0342]. There were no significant 32 
differences between the 12-week programme and brief intervention for either HbA1c or 33 
fasting glucose. Changes over time in blood pressure, quality of life, triglycerides and 34 
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HDL, LDL and total cholesterol were small and there were no significant differences 1 
between groups. No participants reported adverse events related to the intervention. 2 
 3 
Intervention usage is summarised in Table 5. At 3 months, 5% participants in the brief 4 
intervention group had attended a commercial weight management programme, 5 
compared with 68% in the 12-week programme and 69% in the 52-week programme. 6 
Only 1% of participants in all groups attended an NHS-led programme and less than 1% 7 
used weight-loss medication. For participants referred to the behavioural programmes, 8 
the mean number of sessions attended was 8.4 (SD 4.2) in the 12-week programme and 9 
28.2 (SD 14.8) in the 52-week programme.  Full details of the economic evaluation are 10 
in the web appendix. In brief, intervention costs, including GP referral time, are 11 
estimated as £18.50 (brief intervention), £60 (12-week programme) and £195 (52-week 12 
programme).  There were no significant differences between groups in health care 13 
resource use per participant at baseline and throughout follow-up. The estimated 14 
incremental NHS cost per additional kg weight loss (expressed here as £/kg) was £91/kg 15 
for the 12-week programme  and £159/kg for the 52-week programme.  Analysis using a 16 
1-year time horizon for consistency with other studies, reduced the ICER to £26/kg and 17 
£75/kg respectively. 18 
The cost-effectiveness acceptability curve (CEAC, web appendix Figure A2) is based on 19 
weight loss at 2 years and includes all NHS costs incurred during that time.  If decision-20 
makers are willing to pay at least £60/kg, then the 12-week programme would be the 21 
preferred strategy.  If decision-makers are willing to pay £200/kg, then the 52-week is 22 
the preferred strategy. If costs are restricted to intervention-only costs, the 52-week 23 
programme becomes the preferred strategy at £100/kg.  24 
Microsimulation modelling estimated that over 25 years after the baseline year, the 12-25 
week programme was cost-saving (dominant) compared with the brief intervention. The 26 
52-week programme was cost-effective relative to both the brief intervention (ICER = 27 
£2498/QALY) and the 12-week programme (£3804/QALY).  28 
In comparison to the brief intervention, the 12-week programme resulted in 623 fewer 29 
incident cases of disease, 643 additional QALYs, and a cost-saving of approximately 30 
£68,000 per 100,000 individuals. In comparison to the 12-week programme, the 52-31 
week programme resulted in 1786 fewer incident cases of disease and generated 1282 32 
additional QALYS, at a cost of approximately £4·9 million per 100,000 individuals. 33 
Further details are included in the web appendix.  34 
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DISCUSSION 1 
Adults in primary care with overweight or obesity who were referred to an open-group 2 
behavioural weight management programme lost 2·7 kg  (±1.2) more weight at 1-year 3 
follow up than those who were given brief advice and self-help materials. Those who 4 
were referred to this behavioural programme for 52-weeks lost 2·1 kg (±0.9) more 5 
weight than those who were referred for 12 weeks. Fifty-seven percent of participants 6 
referred to the 52-week programme lost more than 5% weight, compared with 42% 7 
referred to the 12-week programme and 25% of those in the brief intervention group. 8 
Five percent is often used as a cut-off for clinically significant weight loss, although even 9 
smaller weight losses are associated with improvements in markers of cardiovascular 10 
disease risk.20 On average all groups regained some of the weight lost and at 2-years the 11 
difference in weight loss between the 12-week programme and the brief intervention 12 
was no longer significant, whereas the weight loss in the 52-week programme was 13 
significantly greater than both other groups. Participants in the 52-week programme also 14 
had larger reductions in waist circumference, fat mass, fasting glucose and HbA1c than 15 
participants in the 12-week programme and the brief intervention. When the impact of 16 
the 12-week programme was modelled over 25 years, it was cost-saving compared with 17 
the brief intervention. Although the 52-week programme was more expensive in the 18 
within-trial analysis, when the impact was modelled over 25 years, it resulted in the 19 
greatest gain in QALYs and the greatest reduction in disease incidence. By standards set 20 
by the National Institute of Health and Care Excellence, the intervention is cost-effective 21 
in comparison to both the brief intervention and the 12-week programme. It should be 22 
noted that this assessment of cost-effectiveness does not include potential further 23 
savings in social care and indirect healthcare costs. It also uses a flat rate cost for each 24 
intervention, when in practice full costs would not be incurred if people did not complete 25 
the course, thus potentially overestimating intervention costs. 26 
A strength of this trial is the large patient group that is broadly generalisable to the UK 27 
population. In our previous trial13, participants with a BMI 27-35 kg/m2 were identified 28 
during routine consultations and recruited to the trial.  The current trial was more 29 
inclusive (BMI 28-68 kg/m2) and participants were recruited by letter based on weight 30 
records. In the former, the mean BMI was 31·4 kg/m2 whereas in the present study 31 
participants had a mean BMI of 34·5 kg/m2, more comparable to the population typically 32 
referred to open-group behavioural programmes in NHS referral schemes.21 Mailing 33 
invitations to all eligible patients resulted in a higher proportion of male participants than 34 
seen in routine referral schemes,13,21 although this is still lower than the proportion of 35 
males in the UK population.22 More than half of participating practices were from areas 36 
with an index of multiple deprivation that is higher (more deprived) than the national 37 
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median and participants were drawn from a wide range of socioeconomic groups.23  Most 1 
participants were white, with the proportion enrolled reflecting the ethnic make-up of the 2 
UK.22 There was no evidence that the intervention effects varied by gender or socio-3 
economic status.  This is striking given oft-repeated views that these interventions are 4 
not appropriate for men and concerns that individual behavioural interventions 5 
exacerbate socio-economic inequalities in health.24 25 Taken together, the findings 6 
suggest that the intervention effects reported here may be generalisable to the UK adult 7 
population.  Although uptake of the programmes by more deprived populations is 8 
somewhat lower than in less deprived areas23, more targeted schemes, as have been 9 
implemented elsewhere14, might reduce health inequalities.  10 
 11 
Loss to follow up at 1 year was slightly below average for weight loss trials,26 and there 12 
was little attrition between 1 and 2 years. Three different intention-to-treat analyses 13 
were conducted that each make different assumptions about missing data, as well as two 14 
sensitivity analyses. The consistency of effects demonstrates the robustness of our 15 
findings. The pragmatic nature of the trial meant that participants in all groups were free 16 
to use other weight-loss methods during the trial. This reflects how these interventions 17 
are routinely delivered and allows direct translation of these findings to clinical practice. 18 
Only a tiny minority of participants in each arm used other NHS interventions or weight-19 
loss medications, and only a small proportion of participants who were assigned to the 20 
brief intervention group went on to use a commercial weight loss programme. A strength 21 
of this trial is the 2-year follow up of participants, which gives important information on 22 
weight trajectories after treatment ends. The modelled cost-effectiveness over 25 years 23 
is based on assumptions about weight trajectories beyond 2 years, however we have 24 
been relatively conservative in these assumptions, assuming all weight lost is regained 25 
within 5 years. The within-trial ICERs are strongly affected by non-significant differences 26 
between groups in healthcare costs (highest in the 52-week programme and lowest in 27 
the 12-week programme) based on health-care usage data in 46.7% participants. 28 
However, sensitivity analyses (web appendix) provide information with which to assess 29 
the strength of these findings. Fasting status when blood was taken and attendance at 30 
Weight Watchers were self-reported and could be susceptible to reporting/recall bias.   31 
Reliance on subjects confirming that the blood sample was taken in a fasting state is a 32 
universal concern in any free-living study and findings related to glucose were congruent 33 
with findings for HbA1c, which is not affected by fasting status. Attendance at Weight 34 
Watchers was self-reported and could be susceptible to reporting/recall bias. However, 35 
any bias in the attendance data does not impact the pre-specified outcomes which were 36 
conducted on an intention-to treat basis. 37 
 38 
 15 
 
The weight losses seen in this study are consistent with previous trials of 12 weeks and 1 
52 weeks referral to commercial open-group behavioural weight management 2 
programmes, suggesting findings are robust.13,14,27 Estimates of the mean incremental 3 
cost per additional kg lost for either duration of treatment are within the range of other 4 
behavioural programmes (web appendix Table A4). The reductions in fasting glucose and 5 
HbA1c were not seen in our previous trial of the 52-week programme,
28 perhaps because 6 
the lower baseline BMI and stricter inclusion criteria in that study meant that participants 7 
had lower baseline values. Almost half of participants in the current trial had elevated 8 
fasting glucose and/or HbA1c at baseline. Reductions seen in the 52-week programme 9 
participants at 12 months (-0·5 mmol/l fasting glucose and –2·8 mmol/mol HbA1c) are 10 
larger than those seen at the same timepoint in the intensive lifestyle intervention arm 11 
of the Diabetes Prevention Programme (DPP; approximately -0·4 mmol/l fasting glucose 12 
and  -1 mmol/mol HbA1c)
29, whose participants were similar to those in the current study 13 
in baseline BMI, HbA1c and glucose and had similar weight loss at 12 months, but 14 
achieved at a fraction of the cost.30 Notwithstanding gradual weight regain and increase 15 
in associated risk factors observed over 15 years follow-up, DPP achieved a 27% 16 
reduction in the cumulative incidence of diabetes in the lifestyle intervention relative to 17 
the control group.31 However the impact of these more scalable interventions on 18 
diabetes incidence will depend on whether longer term weight trajectories are similar.  19 
The programme we evaluated is widely available and participants in the brief 20 
intervention group were neither encouraged nor discouraged from attending other 21 
weight loss programmes. Only 1 in 20 chose to do so, compared with 14 in 20 of those 22 
referred to these programmes. In the 12 week group, 19% of participants were still 23 
attending the programme 12 months later at their own cost, compared with 9% of those 24 
in the brief intervention. This suggests some legacy effect of the initial referral. However, 25 
this is lower than the 42% of participants in the 52-week group who were still attending 26 
at 12 months. As the median household income was about £30,000, it is likely that 27 
many people would have been able to pay the cost of the programme (approximately 28 
£5/week) suggesting it may be the act of referral itself that is the source of motivation 29 
to attend, though it is impossible to exclude that lower attendance in other groups was 30 
related to the cost. The importance of the referral is supported by qualitative data that 31 
found the GP referral is perceived as an implicit recommendation of the programme and 32 
the allocation of NHS resources to enabling their attendance increases motivation to 33 
attend.32  It is also supported by another trial among people with obesity attending a GP 34 
consultation unrelated to their weight, where 77% who agreed to participate in the trial 35 
and were offered a referral to a weight management programme accepted it and 40% 36 
attended.33  37 
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The absolute weight loss among participants receiving only the brief intervention 1 
warrants consideration. Participants given 5 minutes of non-tailored advice and a self-2 
help booklet lost over 3 kg at 12 months and over 2 kg at 24 months. Weight change in 3 
this group is larger than the average weight loss observed in a recent meta-analysis3 for 4 
interventions led by generalist primary care teams, and larger than the average weight 5 
loss seen in a systematic review of self-help interventions.34 Given the small cost of this 6 
intervention (self-help booklet and three short appointments that could be delivered by a 7 
nurse or health care assistant), observational data would support the implementation of 8 
this intervention as a minimal standard in primary care. However, this finding highlights 9 
the importance of including a control group when evaluating weight loss interventions. A 10 
recent review has shown that control groups given minimal interventions will generally 11 
lose weight over the course of a trial.35 In this review there was considerable 12 
heterogeneity in the absolute weight loss of control groups, which may reflect differences 13 
in study populations and trial design. The current trial illustrates this showing 3·4 kg 14 
weight loss in a minimal contact control group, when an almost identical brief 15 
intervention achieved less than 1 kg weight loss when used as a control group in a 16 
different population and context.36 17 
This trial demonstrates that referral to this commercial open-group behavioural weight 18 
loss programme increases weight loss relative to a brief intervention in primary care. 19 
Increasing the duration of the programme from 12 weeks to 52 weeks increases weight 20 
loss and improvements in other markers of diabetes and cardiovascular risk, most 21 
notably glycosylated haemoglobin and fasting glucose. Economic evaluation of this trial 22 
found that while the 52-week programme requires greater initial investment, it is likely 23 
cost-effective in the longer-term and commissioners should consider a move towards 24 
extended referral schemes. 25 
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Research in context panel 1 
Evidence before this study  2 
A systematic review and meta-analysis conducted in November 2012 synthesised data 3 
from 37 trials of behavioural weight management programmes delivered in a context 4 
that could be replicated in routine clinical practice. Three studies evaluated primary care 5 
referral to a commercial open-group programme in comparison to a control group and 6 
pooled results found a mean difference of 2.22 kg in favour of the intervention group, 7 
but no consistent effects on markers of cardiovascular risk. The quality of the evidence 8 
was assessed as moderate. These interventions lasted 12, 52, and 104 weeks with no 9 
studies comparing effectiveness with different durations of treatment. Indirect 10 
comparisons across all 37 studies found no effect of duration of intervention on weight 11 
loss at 12 months. However, a previous systematic review and meta-analysis of direct 12 
comparisons between interventions of different lengths, mostly from controlled research 13 
studies, found that interventions providing ‘extended care’ led to 3·2 kg less weight 14 
regain than control interventions over a mean follow up period of 17·6 months following 15 
initial weight loss. An updated search of Pub Med and Scopus (to 12th January 2017) 16 
found no new direct comparisons of treatment duration. 17 
Added value of this study  18 
In a large randomised controlled trial in a sample broadly generalisable to the UK 19 
population, this trial finds that referral to a commercial programme for 12 weeks or 52 20 
weeks produces greater weight loss than a brief self-help intervention. It extends 21 
previous findings by demonstrating that referral for 52 weeks achieves significantly 22 
greater weight loss than the standard 12-week referrals currently used in the UK 23 
National Health Service over 2 years. Contrary to common criticisms that these 24 
interventions could exacerbate health inequalities, there was no evidence that the 25 
outcome of treatment is moderated by socioeconomic factors such as gender, education 26 
and income.We also show, for the first time, that this extended referral achieves 27 
improvements in fasting glucose and glycosylated haemoglobin equivalent to more 28 
intensive health professional-led interventions. Using microsimulation modelling, we 29 
show for the first time that over a 25-year period the 12-week programme is cost-saving 30 
compared with a brief intervention, and that the 52-week programme is cost-effective 31 
compared with the 12-week programme.  32 
Implications of all the available evidence 33 
Referral to a commercial open-group behavioural weight loss programme for 12 weeks is 34 
an effective weight loss intervention and could be cost-saving for adults in the general 35 
population in the long term. Extending the referral length from 12 weeks (UK standard) 36 
to 52 weeks would significantly increase the clinical effectiveness of these programmes, 37 
by achieving greater weight loss and reductions in risk factors for diabetes and 38 
cardiovascular disease. While the 52-week programme is more expensive in the short 39 
term, in the longer term it would likely be cost-effective because of greater reductions in 40 
disease incidence. 41 
 42 
1269 Recruited and Randomised 
528 allocated to CP52 
455 completed  
3 month assessment 
360 completed  
12 month assessment 
528 included in intention to 
treat analyses 
29 withdrew consent 
44 did not attend 
33 withdrew consent 
103 did not attend 
3 deceased 
530 allocated to CP12 
405 completed  
3 month assessment 
339 completed  
12 month assessment 
528 included in intention to 
treat analyses 
2 excluded (ineligible)† 
62 withdrew consent 
60 did not attend 
1 deceased 
29 withdrew consent 
99 did not attend 
1 deceased 
211 allocated to BI 
144 completed  
3 month assessment 
124 completed  
12 month assessment 
211 included in intention to 
treat analyses 
37 withdrew consent 
30 did not attend 
15 withdrew consent 
35 did not attend 
355 completed  
24 month assessment 
368 completed  
24 month assessment 
133 completed  
24 month assessment 
26 did not attend 6 withdrew consent 
74 did not attend 
12 withdrew consent 
82 did not attend 
1 deceased 
Figure 1: Trial Profile 
Figures
Figure 2: Weight change (SE bars) over time by intervention group, showing mean of all measured weights at each time point 
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Table 1: Baseline characteristics of participants by intervention group 
 
 
 
Brief Intervention 
(N=211) 
12-week Programme 
 (N=528) 
52-week Programme 
 (N=528) 
 N Mean (SD) N Mean (SD) N Mean (SD) 
Age (years) 211 51·9 (14·1) 528 53·6 (13·3) 528 53·3 (14·0) 
Weight (kg) 211 96·1 (16·4) 528 96·6 (17·9) 528 95·7 (16·4) 
Height (cm) 211 167 (9·5) 528 167 (8·9) 528 167 (9·0) 
BMI (kg/m²) 211 34·4 (4·6) 528 34·7 (5·4) 528 34·5 (5·1) 
Fat Mass (kg) 204 39·2 (9·9) 515 39·6 (11·8) 517 39·4 (11·1) 
Waist (cm) 210 110 (11·9) 528 111 (12·4) 528 110 (12·7) 
Systolic Blood Pressure (mmHg) 210 130·6 (15·7) 526 133·5 (17·2) 527 133·3 (18·1) 
Diastolic Blood Pressure (mmHg) 210 79·7 (9·2) 526 80·7 (9·7) 527 79·9 (10·0) 
Fasting Glucose (mmol/L) 134 5·8 (1·9) 345 5·6 (1·6) 326 5·8 (1·8) 
HbA1c (mmol/mol) 143 41·9 (11·2) 354 40·9 (9·8) 338 41·7 (10·4) 
Triglycerides (mmol/L) 146 1·6 (0·9) 357 1·6 (0·8) 339 1·5 (0·7) 
Cholesterol (mmol/L) 146 5·5 (1·2) 357 5·3 (1·1) 337 5·3 (1·1) 
LDL Cholesterol (mmol/L) 145 3·1 (1·2) 353 3·0 (1·0) 339 2·9 (1·0) 
HDL Cholesterol (mmol/L) 146 1·6 (0·6) 357 1·6 (0·6) 339 1·7 (0·6) 
Quality of Life (EQ5D-3L tariff) 197 0·786 (0.266) 508 0·783 (0.249) 504 0·793 (0.249) 
Quality of Life (EQ-Vas) 201 70.3 (18.9) 515 70.9 (18.0) 506 70.0 (19.9) 
 
 N (%)  N (%)  N (%) 
Sex       
  Female   143 (68)  357 (68)  359 (68) 
  Male   68 (32)  171 (32)  169 (32) 
Gross Household Income pa       
    <£20,000  65 (31)  125 (24)  138 (26) 
    £20,000 - £39,999  56 (27)  132 (25)  137 (26) 
    ≥£40,000  51 (24)  132 (25)  123 (23) 
    Missing/Prefer not to say  39 (18)  139 (26)  130 (25) 
Ethnicity       
    Asian/Asian British  9  (4)  11 (2)  15 (3) 
    Black/Black British  5  (2)  12 (2)  6 (1) 
    Mixed/Multiple Ethnic Group  4  (2)  4 (1)  7 (1) 
    White/White British  181(86)  480 (91)  475 (90) 
    Other  2  (1)  6 (1)  7 (1) 
   Missing/Prefer not to say  10  (5)  15 (3)  18 (3) 
Education       
   Higher Degree or equivalent  23 (11)  79 (15)  68 (13) 
   University Degree or equivalent  48 (23)  108 (20)  97 (18) 
   Post-secondary Education  10 (5)  14 (3)  10 (2) 
   A-Levels or equivalent  53 (25)  95 (18)  110 (21) 
   GCSEs or equivalent  55 (26)  153 (29)  155 (29) 
   None  7 (3)  25 (5)  27 (5) 
   Missing/Prefer not to say  15 (7)  54 (10)  60 (11) 
Table
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Table 2: Changes in weight from baseline (mean, SE) at 3, 12, and 24 months by intervention group  
 
      
Test 1 (One-sided) 
 
Test 2 (Two-sided) 
  
Intervention 
 
Adjusted Difference (95%CI) 
 
Adjusted Difference (95%CI) 
 
N 
Brief 
Intervention 
12-week 
Programme 
52-week 
Programme  
Behavioural Programme  
vs Brief Intervention 
p-value 
 
52-week Programme  
vs 12-week Programme 
p-value 
3 months 1267 -2·04 (0·30) -4·84 (0·19) -4·62(0·17)   -2·67 (-3·28, -2·07) <0·0001   0·22 (-0·26, 0·69) 0·371 
12 months 1267 -3·26 (0·68) -4·75 (0·35) -6·76 (0·42)   -2·71 (-3·86, -1·55) <0·0001   -2·14 (-3·05, -1·22) <0·0001 
24 months 1267 -2.30 (0.73) -3.00 (0.37) -4.29 (0.44)  -1.44 (-2.87, -0.00) 0.0247  -1.32 (-2.46, -0.18) 0.0231 
 
BP = Behavioural Programme; CP12 = 12 weeks commercial programme; CP52 = 52 weeks commercial programme  
 
Missing at random analysis; uses 20 imputed data sets. Treatment effects obtained from mixed effects models with residuals structured as a first-order 
auto-regressive process stratified by treatment group. 
 
Adjusted differences are shown between combined treatment groups (CP12 and CP52) and BI (Test 1) and CP52 versus CP12 (Test2)  
Analyses are adjusted for baseline observation and centre 
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Table 3: Proportion of participants losing at least 5% and at least 10% baseline weight at 12 and 24 months by 
intervention, and Relative Risk for combined behavioural programmes versus brief intervention and for 52-week 
programme vs the 12-week programme.   
 
 
 
 
 
 
  
  Brief 
Intervention 
%(SE) 
12-week 
Programme 
%(SE) 
52-week 
Programme 
%(SE) 
Behavioural Programme 
vs Brief Intervention 
52-week Programme 
vs 12-week Programme 
  Relative Risk (95%CI) p-value Relative Risk (95%CI) p-value 
≥5% weight 
loss 
12 months 25 (2.97) 42 (2.15) 57 (2.16) 2.01 (1.51, 2.67) <0.0001 1.36 (1.14, 1.62) 0.0005 
24 months 22 (2.87) 27 (1.93) 39 (2.12) 1.47 (1.08, 1.99) 0.0131 1.44 (1.16, 1.78) 0.0009 
≥10% 
weight loss 
12 months 9 (2.02) 15 (1.56) 30 (2.00) 2.40 (1.52, 3.78) 0.0002 2.00 (1.53, 2.62) <0.0001 
24 months 9 (1.93) 12 (1.43) 18 (1.69) 1.80 (1.11, 2.93) 0.0182 1.49 (1.09, 2.04) 0.0125 
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Table 4: Changes from baseline (mean, SE) in secondary outcomes at 3, 12 and 24 months by intervention and adjusted differences between each intervention 
    Intervention Adjusted Difference (95%CI) Adjusted Difference (95%CI) Adjusted Difference (95%CI) 
  N 
Brief 
Intervention 
12-week 
Programme 
52-week 
Programme 
52-week Programme  
vs Brief Intervention p-value 
12-week Programme  
vs Brief Intervention p-value 
52-week Programme  
vs 12-week Programme p-value 
3  month changes            
Waist (cm) 1266 -2·42 (0·49) -4·66 (0·25) -4·20 (0·25) -1·78 (-2·71, -0·84) 0·0002 -2·32 (-3·25, -1·39) <0·0001 0·54 (-0·08, 1·17) 0·089 
Fat mass (kg) 1236 -1·59 (0·30) -3·95 (0·18) -3·50 (0·14) -1·85 (-2·43, -1·27) <0·0001 -2·31 (-2·90, -1·72) <0·0001 0·46 (0·04, 0·88) 0·0324 
Systolic BP (mmHg) 1263 -2·39 (1·01) -5·50 (0·66) -5·25 (0·61) -2·82 (-5·11, -0·53) 0·0158 -3·32 (-5·66, -0·98) 0·0054 0·50 (-1·24, 2·25) 0·571 
Diastolic BP (mmHg) 1263 -2·59 (0·65) -4·27 (0·41) -3·64 (0·37) -1·02 (-2·47, 0·42) 0·164 -1·78 (-3·25, -0·31) 0·0174 0·76 (-0·32, 1·83) 0·166 
Quality of Life (EQ5D-3L tariff) 1209 
-0.011 
(0.016) 0.012 (0.009) 0.002 (0.009) 0.011 (-0.026, 0.047) 0.562 0.023 (-0.013, 0.060) 0.214 -0.013 (-0.036, 0.011) 0.298 
12 month changes           
Waist (cm) 1266 -3·18 (0·64) -5·15 (0·43) -7·28 (0·45) -4·05 (-5·54, -2·56) <0·0001 -2·12 (-3·59, -0·65) 0·0048 -1·93 (-3·01, -0·85) 0·0005 
Fat mass (kg) 1236 -2·48 (0·55) -3·71 (0·33) -5·05 (0·35) -2·84 (-3·91, -1·77) <0·0001 -1·40 (-2·47, -0·33) 0·0102 -1·44 (-2·22, -0·66) 0·0003 
Systolic BP (mmHg) 1263 -2·77 (1·16) -3·36 (0·73) -3·74 (0·87) -1·04 (-3·64, 1·56) 0·433 -0·59 (-3·18, 2·01) 0·657 -0·45 (-2·49, 1·59) 0·664 
Diastolic BP (mmHg) 1263 -1·64 (0·87) -2·31 (0·43) -2·71 (0·51) -1·20 (-2·98, 0·58) 0·186 -0·75 (-2·52, 1·01) 0·403 -0·45 (-1·70, 0·80) 0·483 
Fasting Glucose (mmol/L) 800 -0·11 (0·20) -0·27 (0·10) -0·54 (0·08) -0·46 (-0·88, -0·03) 0·0342 -0·17 (-0·59, 0·26) 0·436 -0·29 (-0·58, -0·00) 0·0497 
HbA1c (mmol/mol) 835 0·15 (0·69) -1·49 (0·37) -2·77 (0·47) -2·65 (-4·28, -1·01) 0·0015 -1·34 (-2·96, 0·29) 0·107 -1·31 (-2·47, -0·15) 0·0268 
Triglycerides (mmol/L) 837 -0·14 (0·07) -0·23 (0·05) -0·26 (0·03) -0·09 (-0·25, 0·07) 0·281 -0·06 (-0·22, 0·10) 0·451 -0·03 (-0·14, 0·09) 0·646 
Cholesterol (mmol/L) 837 -0·31 (0·10) -0·32 (0·05) -0·36 (0·05) -0·05 (-0·24, 0·14) 0·625 -0·01 (-0·20, 0·19) 0·938 -0·04 (-0·17, 0·09) 0·556 
LDL cholesterol (mmol/L) 830 0·01 (0·10) 0·02 (0·05) 0·02 (0·05) 0·00 (-0·19, 0·19) 0·9996 -0·00 (-0·19,0·19) 0·976 0·00 ('-0·13, 0·14) 0·964 
HDL Cholesterol (mmol/L) 837 -0·27 (0·04) -0·24 (0·03) -0·24 (0·03) 0·01 (-0·12, 0·13) 0·917 0·03 (-0·10, 0·15) 0·668 -0·02 (-0·11, 0·07) 0·641 
Quality of Life (EQ5D-3L tariff) 1209 
-0·014 
(0·018) 0·009 (0·011) -0·012 (0·011) 0·014 (-0·025, 0·054) 0·476 0·029 (-0·011, 0·069) 0·150 -0·015 (-0·044, 0·014) 0·323 
24 month changes           
Waist (cm) 1266 -3.64 (0.72) -4.36 (0.47) -5.57 (0.45) -1.98 (-3.56, -0.41) 0.0137 -0.72 (-2.27, 0.83) 0.365 -1.27 (-2.46, -0.07) 0.0384 
Fat mass (kg) 1236 -2.24 (0.62) -2.40 (0.32) -3.38 (0.38) -1.36 (-2.64, -0.08) 0.0375 -0.36 (-1.60, 0.88) 0.572 -1.00 (-1.94, -0.07) 0.0359 
Systolic BP (mmHg) 1263 0.64 (1.13) -0.85 (0.87) -0.09 (0.78) -0.52 (-3.07, 2.02) 0.687 -1.22 (-3.75, 1.31) 0.344 0.70 (-1.32, 2.71) 0.497  
Diastolic BP (mmHg) 1263 -0.83 (0.79) -1.29 (0.50) -1.11 (0.50) -0.22 (-1.97, 1.52) 0.803 -0.32 (-2.05, 1.40) 0.713 0.10 (-1.13, 1.34) 0.872  
Quality of Life (EQ5D-3L tariff) 1209 
-0.005 
(0.018) -0.015 (0.012) -0.018 (0.011) -0.014 (-0.052, 0.025) 0.486 -0.011 (-0.050, 0.028) 0.587 -0.003 (-0.032, 0.027) 0.843 
 
Analyses adjusted for baseline observation and centre.  Mean weight change analyses use 20 imputed data sets. Treatment effects obtained from mixed effects models 
with residuals structured as a first-order auto-regressive process stratified by treatment group 
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Table 5: Self-reported intervention usage in the previous three months, recorded at 3, 12, and 24 months 
  3 month visit 12 month visit 24 month visit 
  BI 12W 52W BI 12W 52W BI 12W 52W 
Attendance questionnaire returned  N 132 382 436 108 321 342 115 321 330 
Attended ≥1 meeting of a commercial weight 
loss programme in last 3 months 
N 
% of responders 
7 
5.3% 
259 
67.8% 
300 
68.8% 
10 
9.3% 
60 
18.7% 
143 
41.8% 
14 
12.2% 
44 
13.7% 
57 
17.3% 
Attended ≥9 meetings of a commercial weight 
loss programme in last 3 months 
N 
% of responders 
3 
2.3% 
199 
52.1% 
216 
49.5% 
8 
44.4% 
47 
14.6% 
100 
29.2 
7 
6.1% 
25 
7.8% 
38 
11.5% 
Attended an NHS-led programme in last 3 
months  
N 
% of responders 
1 
0.8% 
4 
1.0% 
5 
1.1% 
2 
1.9% 
3 
0.9% 
2 
0.6% 
4 
3.5% 
1 
0.3% 
2 
0.6% 
Used weight loss medication in last 3 months  N 
% of responders 
0 
0% 
1 
0.3% 
2 
0.5% 
0 
0% 
0 
0% 
1 
0.3% 
1 
0.9% 
0 
0% 
1 
0.3% 
 
BI = Brief Intervention; 12W = 12-week programme; 52W = 52-week programme  
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Weight loss referrals for adults in primary care
(WRAP): protocol for a multi-centre randomised
controlled trial comparing the clinical and
cost-effectiveness of primary care referral to a
commercial weight loss provider for 12 weeks,
referral for 52 weeks, and a brief self-help
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Abstract
Background: Recent trials demonstrate the acceptability and short term efficacy of primary care referral to a
commercial weight loss provider for weight management. Commissioners now need information on the optimal
duration of intervention and the longer term outcomes and cost effectiveness of such treatment to give best value
for money.
Methods/Design: This multicentre, randomised controlled trial with a parallel design will recruit 1200 overweight adults
(BMI ≥28 kg/m2) through their primary care provider. They will be randomised in a 2:5:5 allocation to: Brief Intervention,
Commercial Programme for 12 weeks, or Commercial Programme for 52 weeks. Participants will be followed up for two
years, with assessments at 0, 3, 12 and 24 months. The sequential primary research questions are whether the CP
interventions achieve significantly greater weight loss from baseline to 12 months than BI, and whether CP52 achieves
significantly greater weight loss from baseline to 12 months than CP12. The primary outcomes will be an intention to
treat analysis of between treatment differences in body weight at 12 months. Clinical effectiveness will be also be
assessed by measures of weight, fat mass, and blood pressure at each time point and biochemical risk factors at
12 months. Self-report questionnaires will collect data on psychosocial factors associated with adherence, weight-loss and
weight-loss maintenance. A within-trial and long-term cost-effectiveness analysis will be conducted from an NHS
perspective. Qualitative methods will be used to examine the participant experience.
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Protocol
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Discussion: The current trial compares the clinical and cost effectiveness of referral to a commercial provider with a brief
intervention. This trial will specifically examine whether providing longer weight-loss treatment without altering content
or intensity (12 months commercial referral vs. 12 weeks) leads to greater weight loss at one year and is sustained at
2 years. It will also evaluate the relative cost-effectiveness of the three interventions. This study has direct implications for
primary care practice in the UK and will provide important information to inform the decisions of practitioners and
commissioners about service provision.
Trial Registration: Current Controlled Trials ISRCTN82857232. Date registered: 15/10/2012.
Keywords: Obesity, Weight-loss, Primary care, Adults
Background
Obesity has trebled since the 1980s and globally, excess
weight is estimated to account for 44% of diabetes, 23%
of ischemic heart disease and 7-41% of some cancers [1].
There is good evidence that intensive lifestyle interven-
tions can produce weight loss linked to clinically signifi-
cant health benefits [2], but such specialist interventions
are costly given the high prevalence of obesity. Interven-
tions delivered in primary care can also be demanding in
terms of staff resources, set up and training and partici-
pant weight loss is often less than 5% of initial weight
[3,4]. In the UK, NICE recommends consideration of
any intervention that meets best practice, including re-
ferral to commercial weight loss programmes [5]. Com-
mercial programmes are usually delivered in large
groups by lay people, and preliminary evidence suggests
they may be more affordable than interventions led by
health professionals, making weight loss initiatives avail-
able for more individuals [6,7].
A number of commercial weight loss providers currently
operate referral schemes for Public Health and the National
Health Service (NHS) in the UK, whereby commissioners
can purchase 12 week referral packages at a reduced cost,
which are provided at no cost to patients. Two randomised
controlled trials conducted by members of the current re-
search team have demonstrated the effectiveness of com-
mercial referrals. Jolly et al. compared a number of 12 week
weight loss interventions in Birmingham’s Lighten Up ser-
vice, including three commercial providers, to a control
intervention (12 vouchers to attend a leisure centre) [8].
Twelve-month weight loss was significantly greater among
participants referred to a commercial programme (Weight
Watchers; WW) than control participants [−4.35 ± 6.9 kg
vs −1.63 ± 6.0 kg; p < 0.001]. Jebb et al. [9] demonstrated
that overweight and obese adults referred to this commer-
cial programme by their primary care provider for
12 months lost twice as much weight as those who received
standard care [−5.1 ± 6.1 kg vs 2.3 ± 4.2 kg; p < 0.001].
These findings suggest that referral to a commercial
programme (CP) by a primary care provider is a clinically
effective weight loss intervention over a one year period.
However, limited data on participants who agreed to attend
further follow up suggests significant weight regain beyond
programme end [10].
The NHS currently provides 12 week referrals to com-
mercial programmes. There is conflicting evidence on
whether providing longer treatment interventions could re-
sult in greater and more sustained weight loss. In one
meta-analysis of studies providing ‘extended care’ , partici-
pants receiving extended care had, on average, 3.2 kg less
weight regain than controls over a mean follow up period
of 17.6 months [11]. The reduced weight regain in the ex-
tended care intervention in studies with 6–12 month
follow-up was at least 1.5 kg. However, in a recent review
of behavioural weight management programmes, meta-
regression of trials with longer and shorter programmes
found no benefit of longer programmes up to 1 year [12].
Indirect comparisons from Jebb et al. and Jolly et al. suggest
that 12 months CP (weight loss 5.1 kg) achieves greater loss
than 12 weeks CP (weight loss 4.4 kg, assessed at
12 months). The difference is small, but participants in Jolly
at al. were heavier and older than those in the Jebb et al.,
two factors associated with greater weight loss in an audit
of the CP’s NHS referral database [13] and an observational
analysis of the routine Lighten Up service [14]. Thus we
might anticipate the difference in weight loss after 12 or
52 weeks intervention in comparable groups to be greater
than the comparison between these two studies. Moreover,
further analysis of Jolly et al. suggests the apparent impact
of the WW intervention may have been atypically high. In
the two other commercial providers (Slimming World and
Rosemary Conley), mean weight loss at 12 months was
smaller than WW, yet a much larger comparison (n =
3000) of the three providers in the routine Lighten-Up re-
ferral service shows that mean self-reported weight loss at
1 year in those attending WW was very close to the mean
weight loss across all providers [14]. Mean 12 month weight
loss for the three CPs in Jolly et al. was 2.7 kg, giving an as-
sumed difference of 1.36 kg between this and the 52 weeks
intervention in Jebb et al. A formal RCT is needed to show
whether the greater loss in the 12 month programme is due
to the longer referral and the current trial will directly com-
pare weight loss at 12 months for participants receiving
12 weeks referral (CP12) and 52 weeks referral (CP52).
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Obesity is a chronic, relapsing condition and the sus-
tainability of weight loss achieved in short term inter-
ventions cannot be assumed. There is currently no
published data on 12 week commercial referral out-
comes beyond 12 months. In the limited data from par-
ticipants from Jebb et al., 12 months CP did lead to
greater weight loss than standard care, but this differ-
ence was small and sensitive to assumptions about miss-
ing data [10]. We will therefore follow participants up
for 24 months to examine whether any initial differences
in weight loss are sustained in the longer term.
Careful consideration has been given to the most appro-
priate control intervention. Since in many cases, obesity re-
mains untreated in primary care, a no-intervention control
may be considered to reflect standard care. However, recog-
nition of obesity by GPs as part of recruitment to the trial
and appointments for outcome measurements may consti-
tute an intervention in its own right and in a recent review
even minimal intervention ‘control’ groups lost weight [12].
Where offered, weight management interventions in pri-
mary care vary considerably. Since this is not the focus of
this trial it is important to have a standardised ‘control’
intervention. Inclusion of a brief intervention based on
written self-help materials will allow us to control for the
impact of the GP offering a weight loss intervention and
trial participation on weight loss and allow some consider-
ation of the relative contribution of engagement and
follow-up versus the nature and content of the specific
intervention provided.
For NHS commissioners, one of the most important
questions is whether an intervention offers value for money
and a rigorous evaluation of cost-effectiveness has been
built into the trial. Data on treatment costs, health-care
usage and quality of life [15] will enable us to model
whether any additional weight loss achieved through the
52 week programme is worth the additional costs. Initially
this will consider cost-effectiveness from the perspective of
the NHS, within the period of the trial (i.e. 24 months),
However, ultimately, we want to know whether the inter-
ventions are likely to lead to an increase in length and qual-
ity of life, and at what cost. It is not practical to conduct a
prospective study with lifetime follow up to establish this.
Instead we propose using a well-developed decision-
analytic model to estimate the long term impact of weight
loss on risks of chronic disease and hence quality adjusted
life years (QALYs) and cost.
Qualitative data suggests neither participants nor prac-
titioners view weight management services as a priority
in primary care and that some resist the idea that it is a
medical issue in and of itself [16]. Thus, by delivering
the intervention outside of a medical context, a CP fits
better with participants’ own view of weight manage-
ment. This study will examine participant experience in
greater depth to explore the ways in which individuals
understand and make sense of the imperative to lose
weight, and the values and tensions arising from the pri-
mary care- commercial provider relationship. It will also
examine the extent to which the weekly weigh in and
the sense of peer support are experienced to be key as-
pects of the CP and the extent to which these are felt to
facilitate weight loss.
Interventions for weight management could potentially
be improved by developing a greater understanding of the
psychosocial factors that explain individual variation in ad-
herence, weight loss and post-intervention weight mainten-
ance. There is a particular lack of knowledge about how
these factors change during weight loss and how they affect
weight maintenance. The current study will use validated
questionnaires to explore a number of psychosocial factors
that have either demonstrated an association with attrition,
weight loss, and maintenance of weight lost in previous
studies, or represent constructs identified as potentially
important predictors of weight loss maintenance in
recent reviews [17-19]. We will examine how baseline
differences in these factors affect weight trajectories,
how these factors change during and following a weight
loss intervention, and how changes are associated with
changes in weight.
Objectives
Primary objectives
The primary research question is whether the CP inter-
ventions achieve significantly greater weight loss from
baseline to 12 months than BI, and whether CP52
achieves significantly greater weight loss from baseline
to 12 months than CP12.
Secondary objectives
Clinical effectiveness
We will examine differences between the three inter-
ventions in weight, waist circumference, body compos-
ition, and blood pressure at 3, 12 and 24 months and
differences in biochemical measures (blood glucose,
total cholesterol, HDL cholesterol, LDL cholesterol, and
HbA1c) at 12 months. Specifically we will test the fol-
lowing hypotheses:
i) Both CP interventions achieve significantly greater
weight loss than BI from baseline to 3 months and
baseline to 24 months and CP52 produces
significantly greater weight loss than CP12 from
baseline to 24 months.
ii) Both CP interventions achieve significantly greater
improvements in waist circumference, body
composition and blood pressure than BI between
baseline and 3, 12 and 24 months.
iii) CP52 achieves significantly greater improvements in
waist circumference, body composition and blood
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pressure than CP12 between baseline and 3, 12 and
24 months.
iv) Both CP interventions achieve significantly greater
improvements in biochemical measures than BI
between baseline and 12 months, and CP52 achieves
significantly greater improvements than CP12.
Cost-effectiveness
We will examine the cost-effectiveness of each of these
interventions. The following hypotheses will be tested:
i. CP52 is more cost-effective than CP12, as assessed
by both within trial cost effectiveness and long term
cost-effectiveness analyses.
ii. Both CP12 and CP52 are more cost-effective
than BI.
Participant experience
A qualitative workstream will explore the attitudes of
participants to primary care referrals to commercial
providers for weight loss, and also their wider experi-
ences of weight management. In line with a qualitative
research methodology, the following three areas will act
as a guide for the research that will also remain sensitive
to the experiences and topics raised by participants:
i) The extent to which participants feel that they have
been referred for weight management in the NHS by
their GP, and how this relates to their experience of
participating in the programme and their attitudes
toward weight loss.
ii) The extent to which the weekly weigh in and the
sense of peer support are experienced to be key
aspects of the CP
iii)The extent to which being ‘overweight’ or ‘obese’ is
considered a medical issue by participants
Psychosocial factors
This study will also examine psychosocial factors that
are associated with completion of the intervention,
weight loss and weight loss maintenance, to enable
greater understanding of who benefits from these
interventions and to inform development of new
interventions.
Biological sampling
This study will collect blood samples in order to exam-
ine changes in markers of risk of CVD and diabetes
(fasting lipids, glucose and glycosylated haemoglobin).
DNA will be collected for subsequent analyses of how
genetic variation effects response to the interventions.
Method
Trial design
This is a multicentre, randomised controlled trial with
a parallel design. Participants will be randomised to one
of three interventions: Brief Intervention (BI), Com-
mercial Programme for 12 weeks (CP12) or Commercial
Programme for 52 weeks (CP52) in an allocation of 2:5:5
(Figure 1).
Population
Overweight and obese adults (BMI ≥ 28) in the UK,
deemed eligible for weight management intervention by
their general practitioner.
Setting
Participants will be recruited through primary care prac-
tices across England by three research centres. MRC
Human Nutrition Research is the coordinating centre.
They will recruit through local practices in Cambridgeshire
and all measurements will be conducted by trained
research staff at the research centre. The University of
Liverpool will recruit through local practices across
Merseyside and all measurements will be conducted by
trained research staff at the research centre. The University
of Oxford will recruit through practices across England
and measurements will be conducted by trained health
professionals (usually a research nurse) in the practice.
Recruitment started in October 2012 and was completed
in February 2014.
Participants
Participants will be 1200 overweight and obese adults in
England, recruited by their local primary care provider.
Inclusion criteria
The inclusion criteria are BMI ≥28 kg/m2, aged ≥18 years,
and willing and able to comply with the study procedures.
For simplicity, we will not vary the BMI criteria by ethnic
group.
Exclusion criteria
The exclusion criteria are: planned or current pregnancy in
the next two years; previous or planned bariatric surgery;
currently following a weight-loss programme (defined as a
structured, prescribed and monitored programme and not
a self-regulated diet); non-English Speaking or with Special
Communication needs that would preclude them from un-
derstanding the study materials and interventions. GP’s will
exclude patients who are inappropriate to invite into the
study, for example patients who are violent/terminally ill/
have a history of an eating disorder. GPs will also be
allowed to define any additional inclusion/exclusion criteria
to meet local practice and will be asked to provide details
on these for the reporting of the study. No further criteria
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will be imposed, thus capturing the population that would
typically be referred to these treatments. Participants re-
ceiving other weight loss treatments, e.g. Orlistat, will not
be excluded as such participants would still be eligible for
commercial referrals in standard practice, but this will be
adjusted for in the analyses. Participants will be randomised
to intervention arms, and thus those receiving additional
treatment should be evenly spread across the interventions
and these treatments will be accounted for in the cost-
effectiveness analyses.
Inclusion of same household partners
Where more than one individual from a household is
eligible and wants to enrol in the study, both members
of the household will be allocated to the same treatment
group (randomising participants at the household rather
than the individual level) but only one person per house-
hold (the first to enrol) will be enrolled as a ‘participant’
who will provide measurements for the trial and attend
follow-up visits. The ‘non-participant’ member(s) of a
household will be referred to as ‘same household part-
ner’, and will attend a ‘baseline’ visit to give consent and
to receive their intervention materials. The ‘same house-
hold partner’ will be asked for consent to obtain their
attendance and weight data from Weight Watchers (if
they are allocated to this arm) through their WW NHS
Referral Database. There is also potential for participants
to be part of a household where other members are
engaged in weight loss programmes, outside of this
study. Therefore, all participants will be asked to provide
information about weight loss activities within their
household, regardless of whether they have a partner in
the study or not.
Recruitment
GP practices will be identified and recruited by the local
Primary Care Research Network (PCRN). Practices will
be targeted that do not have an existing contract with
commercial weight loss services. In this way participants
allocated to the brief intervention will not be denied
standard care.
Based on the 10% recruitment rate from Jolly et al., we
will approach approximately 12000 eligible individuals to
recruit 1200 participants. The primary care provider will
search their electronic registers for eligible individuals
and GPs will screen out those to whom it would be in-
appropriate to send a letter (for example patients known
to have a history of eating disorders or to be terminally
Excluded  
– Planned/Current Pregnancy
– Planned/Previous Bariatric Surgery
– Unable/Unwilling to participate
Baseline Assessment and Randomisation
(N=1200) 
52wks Commercial Programme 
(N=500)
Receive vouchers for 1 year  
Weight Watchers membership
Brief Intervention 
(N=200)
Receive written information about 
weight loss strategies
Enrollment
24 month Assessment 24 month Assessment24 month Assessment
Recruitment
Allocation
Invitations sent to ~12000
Eligible individuals identified 
by primary care provider
3 month Assessment
12 month Assessment 12 month Assessment12 month Assessment
3 month Assessment 3 month Assessment
Follow-Up
1 2wks Commercial Programme 
(N=500)
Receive vouchers for 12 Weight 
Watchers sessions
Same Household Participants
Qualitative 
Interview
N~45
Figure 1 Participant flow diagram.
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ill). The letter will not mention the participant’s weight,
but offers the availability of weight management and also
will give brief details of the trial. Interested participants
will be asked to telephone (on a designated Freephone
number) or email the study co-ordinator at their local
site for further information. A member of the research
team will then describe the trial to the potential partici-
pant, undertake further screening, and, if agreeable, offer
an appointment for baseline assessment and enrolment
in the trial. This will be confirmed by letter, accompan-
ied by a participant information sheet.
We will monitor uptake of the trial by ethnic group
and by gender. GPs will be asked in their search for eli-
gible participants to report summary statistics of the
gender and ethnic composition of the eligible popula-
tion. By comparing the recruited population to the eli-
gible population we will be able to examine whether
take-up of referral differed by ethnicity or gender.
Randomisation
At the first assessment, a member of the research team
trained in taking informed consent will ensure that the
participant understands the trial and has read the par-
ticipant information sheet. They will confirm their eligi-
bility for the study and obtain written consent for their
participation in the trial. Participant details, including
baseline weight, will be entered into an online database
by a member of the research team.
The database will automatically assign participants with a
valid recorded baseline weight to one of three interventions
(BI, CP12, CP52). The randomisation sequence was gene-
rated by the trial statistician and allocates participants in a
2:5:5 allocation stratified by centre and gender, with a block
size of 12. The sequence is unknown to research staff and
participants.
Due to the nature of the intervention and the trial de-
sign, neither participants nor research staff will be
blinded to the intervention allocation.
Withdrawal
Participants are free to withdraw from the trial at any time,
without this affecting their care, by informing a member of
the research team. Participants who withdraw will not be
replaced, and data already collected will be used unless the
participant requests that it be removed.
Participants might choose not to attend the commer-
cial weight loss programme, or may stop attending ses-
sions during the trial. Participants who withdraw from
the intervention will be followed up at assessment ap-
pointments in the same way as other participants unless
they also choose to withdraw from the trial.
Three contact attempts (by different means and at dif-
ferent times) will be made for each follow up appoint-
ment. On the third attempt to schedule an appointment,
or where a participant informs us that they are unable
or unwilling to attend a follow up appointment, a self-
measured weight will be requested. These data will not
be included in the primary analyses but will provide add-
itional data that can be used for sensitivity analyses
where it is considered appropriate.
Interventions
Referral to a commercial provider
Participants who are assigned to the two commercial refer-
ral arms will receive vouchers to attend Weight Watchers
sessions and asked to attend a local meeting that is con-
venient for them. They will be asked not to mention their
participation in the trial to the group leader or other mem-
bers, to make their experience as representative as possible.
CP12: Participants allocated to the 12 week referral
will receive free vouchers to attend 12 Weight Watchers
sessions and access to their internet resources for
16 weeks. This is the package currently used in the
WW NHS Referral Scheme and currently costs the
NHS £55 + VAT.
CP52: Participants allocated to the 52 week referral
will receive free vouchers to attend 52 sessions of
Weight Watchers and access to their internet resources
for 12 months. This packages is estimated to cost the
NHS £190 + VAT.
Brief intervention
The control intervention is a standardised brief interven-
tion: recognition of the problem by the GP (letter of in-
vitation), basic written information on self-help weight
loss strategies provided by a member of the research
team at the baseline visit (British Heart Foundation
Booklet: So you want to lose weight… for good) and
weighing at follow up (coincides with outcome measure-
ments at 3, 12 and 24 months).
Adherence
Attendance at CP meetings will be monitored both
through self-report at assessment appointments and data
collected by WW at weekly meetings (which can be pro-
vided, with consent, through the WW NHS referral
database and tracked using NHS referral ID) and these
data will be controlled for in sensitivity analyses. Similar
information may be available from WW regarding web-
site usage, and this data will be combined with that col-
lected via self-report. We will also collect self-report
data on the extent to which BI participants have used
their self-help materials.
Outcomes
Clinical effectiveness outcomes
The primary outcome will be body weight (kg) at
12 months. Secondary clinical outcomes will be: body
Ahern et al. BMC Public Health 2014, 14:620 Page 6 of 12
http://www.biomedcentral.com/1471-2458/14/620
weight (kg) at 3 and 24 months, whether a participant
has lost ≥5% and ≥10% of initial body weight at 3, 12
and 24 months; waist circumference, body composition,
and blood pressure at 3, 12 and 24 months; blood glu-
cose, total cholesterol, HDL cholesterol, LDL cholesterol,
and HbA1c at 12 months.
Cost-effectiveness outcomes
The incremental cost-effectiveness ratio (ICER) of the inter-
vention is the main outcome of the economic evaluation
and will be expressed as incremental costs per incremental
change in weight/BMI for the within-trial evaluation.
Adverse events
This is a low risk trial with little reason to consider that
adverse events would arise as a result of following any
one of the interventions. Accordingly no formal adverse
event monitoring is planned.
Visits and measurements
Participants will attend measurement appointments at 0,
3, 12 and 24 months. Details of which measures will be
taken at which appointments are summarised in Table 1.
Clinical measurements
All clinical measurements will be made in line with stan-
dardised operating procedures by trained research staff.
Participants will be asked to remove shoes and heavy
clothing items. Height (cm) will be measured in cm
using a stadiometer. Weight and fat mass will be mea-
sured in kg using a Tanita segmental body composition
analyser. Waist circumference (cm) will be measured
using a tape measure, half way between the lowest rib
and the iliac crest. Blood pressure will be measured
using standardised methods.
Biochemical measurements
Biochemical measurements are optional for participants
and taken under separate consent. Blood samples will be
Table 1 Schedule of enrolment, interventions, and assessments
STUDY PERIOD
Enrollment Baseline visit Post allocation Close-out
TIMEPOINT -t1 0 3 months 12 months 24 months
ENROLMENT:
Eligibility screen X X
Informed consent X
Allocation X
INTERVENTIONS:
Brief Intervention X
12 weeks Commercial Programme X X
52 weeks Commercial Programme X X X
ASSESSMENTS:
Height X
Weight X X X X
Fat mass X X X X
Waist Circumference X X X X
Blood Pressure X X X X
Blood Glucose X X
Lipid Profile X X
HbA1c X X
DNA X
Demographics Questionnaire X X X X
Health Care Usage Questionnaire X X X X
EQ5D X X X X
Psychosocial Questionnaires X X X X
Intervention Usage Questionnaires X X X X
Qualitative Interviews (subset only) X
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taken by fully trained research staff in line with standar-
dised operating procedures. For assessment appoint-
ments where blood will be taken (0 and 12 months),
participants will be asked to attend in a fasted state
(no food or drink for 12 hours prior to the appointment).
At baseline and 12 months, participants will provide a
sample of whole blood for analysis of glucose, glycosy-
lated haemoglobin (HbA1c) and lipid profile. At baseline,
an additional sample of whole blood will be collected in
an EDTA tube, frozen at −80 and stored for later extrac-
tion of DNA and outside the trial protocol.
Health care usage measures
At each visit, participants will complete a Health Care
Usage Questionnaire to assess their use of Health Care
Services in the last 3 months.
Psychosocial measures
Participants will complete a series of questionnaires at
or before each assessment to assess psychosocial factors
related to weight control.
The Flexible and Rigid subscales if the Eating Inventory
[20] measure cognitive dietary restraint and distinguish
flexible and rigid dietary restraint strategies.
The Power of Food Scale (PFS) [21] measures indivi-
dual differences in hedonic hunger (hunger in the absence
of energy need).
A visual analogue scale (VAS) will be used to assess
state hunger at the time the questionnaire is completed
[22]. Sensitivity analyses can examine whether this
influences responses to questionnaires about eating
behaviour.
The Self-Report Habit Index (SRHI) [23] is a measure
of behavioural frequency, automaticity and identity,
which has also been used to measure the automaticity of
thoughts, such as body-related cognitions. In the current
study, we will use this measure to examine the extent to
which “watching what I eat” and “exercising regularly”
become automatic and are seen as part of a participant’s
identity, and the extent to which this predicts weight
loss and weight loss maintenance.
The Treatment Self-Regulation Questionnaire; Diet
Self-Regulation Questionnaire (DSRQ) and Exercise Self-
Regulation Questionnaire (ESRQ) measure the extent to
which a participant’s motivation to participate in treat-
ment, eat a healthy diet, or exercise, is autonomous (i.e.
they are motivated by personal reasons) or controlled (i.e.
they are motivated by perceived pressure from others).
The Problem Eating Behaviours Questionnaire (PEBQ)
[24] measures the extent to which particular eating
behaviours are problematic for participants.
The EQ5D [15] is a self-report measure of quality of
life, which will be used to calculated QALYs for the cost-
effectiveness analysis.
We will measure life satisfaction using the Satisfaction
with Life Questionnaire (SLQ) [25] and depression and
anxiety using the Hospital Anxiety and Depression Scale
(HADS) [26].
Qualitative data collection
A subset of participants from the Cambridge centre will
be recruited to participate in a qualitative study. Data
will be collected through semi-structured interviews
with up to 15 participants in each intervention. A
maximum-variation (heterogeneity) sampling technique
will be used to select potential interviewees based on
demographic information obtained during the telephone
screening questionnaire and through a questionnaire at
the baseline visit. At the 3 month visit selected partici-
pants (including some who have dropped out of treat-
ment but not withdrawn from follow-up) will be invited
to participate in an interview. Participants will be offered
the choice between having the interview at their home
or in a private office at the University of Cambridge.
Interviews will not be held where study procedures are
conducted, to reduce associations between the interview
and the measurement visits of the trial in order to
encourage participant’s to speak openly about their expe-
riences of the intervention to which they have been
assigned. Interviews will last approximately one hour
and will follow a general topic guide that will be piloted
with a subset.
Statistical analysis
Analysis design
There is already good evidence to suggest that CP pro-
duces significantly greater weight loss than BI and in the
event that CP is not better than BI then the comparison
of the CP arms would not be of interest. Accordingly we
will conduct a sequential analysis, which will preserve
the Type 1 error of 5% without the need for a multi-
plicity correction such as Bonferroni. The sequential
analysis will consist of the following 2 stages:
i) Test the one-sided hypothesis that weight loss in the
CP groups combined is greater than the weight loss
in the BI arm.
ii) If the first test is significant at the 5% significance
level, then test the two-sided hypothesis that there is
a difference between CP52 and CP12 weight loss at
the 5% significance level.
Sample size calculation
We based the power calculation on data from our pre-
vious trials [8,9] with an expected difference of 2.3 kg
between BI and combined CP, 1.3 kg difference between
CP12 and CP52 (for example, a weight loss of 1.05 kg in
the BI arm, 2.7 kg in the CP12 arm and 4.0 kg in the
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CP52 arm), and an assumed standard deviation of 6 kg.
The statistical testing will be performed sequentially
firstly by comparing CP arms with BI and then only if
significant to then test for a difference between CP12
and CP52. Power is optimised by allocating more parti-
cipants to the CP arms where the smaller difference is
expected. With a sample of 1200 participants allocated
as 200 BI, 500 CP12 and 500 CP52, we will have 99.95%
power for the first test, to detect a difference of 2.3 kg
between BI and combined CP and 92.87% power to
detect a difference of 1.3 kg between CP12 and CP52.
The total power of the study will be 92.82%.
Clinical effectiveness
The primary analyses will assess differences in mean
weight change from baseline to 12 months between the
intervention groups. In order to investigate the impact of
missing data, four analysis approaches will be taken: com-
pleters only, baseline observation carried forward (BOCF),
last observation carried forward (LOCF) and a missing at
random (MAR) analysis using a variance components
model. For the LOCF, BOCF and completers analyses,
fixed effect models for continuous normal data will be
fitted to the 12 month weight data. The fixed effects will
be intervention group, centre and baseline weight. For the
MAR analysis, a model for multivariate normal data with
the same fixed effects will be fitted using measured
weights at each time point using generalised least squares.
Coefficient estimates and their 95% confidence intervals
will be calculated for each fixed effect.
All assumptions of the models will be checked using
appropriate graphs (eq a Q-Q plot of residuals to check
normality, residuals versus predicted values to check
homogeneity of residual variance.) If the residuals are not
normally distributed then the dependent variable may be
transformed to normality, if there is no such transfor-
mation then non-parametric methods will be considered.
Secondary analyses will include analyses of weight
change at 3 and 24 months; changes in blood pressure,
waist circumference and fat mass at 3, 12 and 24 months;
changes in biochemical measures at 12 months. These
will be analysed using the same regression based models.
Numbers of participants in each group achieving ≥5%
and ≥10% weight loss at 12 and 24 months will also be
explored.
Summary tables will be produced to look at the demo-
graphic distribution of the sample (age, sex, initial weight,
BMI); attendance rates; time course of attendance; website
usage.
Cost effectiveness
Within-trial cost-effectiveness
The incremental cost-effectiveness ratio of the intervention
is the main outcome of the economic evaluation and will
be expressed as incremental costs per incremental change
in weight/BMI for the within-trial evaluation. Cost items to
be included will be the cost of the intervention (i.e. cost to
NHS of referral packages and infrastructure related to the
operation of the referral scheme), primary, secondary, and
tertiary health care use associated with weight-related
disease (especially diabetes, coronary heart disease, colon
cancer, and musculo-skeletal disorders). At baseline, partici-
pants will complete a health care usage questionnaire co-
vering health service attendances and any weight loss
treatment for the previous 3 months. This questionnaire
will be completed again at 3, 12 and 24 months. Analysis of
uncertainty will be conducted with a non- parametric boot-
strap of the sampled data to generate a cost-effectiveness
acceptability curve showing the probability that the inter-
vention is cost-effective at various willingness-to-pay
thresholds per unit of outcome. The within-trial cost-
effectiveness analysis will be conducted jointly with the
outcome analysis in year 3 of the study. The data will also
be incorporated into the economic model.
Long term cost-effectiveness
Measuring cost-effectiveness in terms of costs per QALYs
will allow the intervention to be compared with many alter-
native uses of existing NHS budgets. We will use the UK
Health Forum’s “Obesity Micro-simulation Model”. The es-
timates the future burden of diseases by making evidence
based extrapolations of selected risk factors specific to the
following BMI related diseases; currently hypertension and
stroke, diabetes mellitus type 2, cardiovascular diseases in-
cluding angina pectoris, myocardial infarction, musculo-
skeletal disorders including osteoarthritis, low back pain
and knee arthrosis; obesity associated cancers including
colorectal, endometrial, ovarian, breast, cervical, prostate
and possibly also gallbladder, pancreatic and renal. The
micro-simulation incorporates a sophisticated economic
module. The module employs Markov-type simulation of
long-term health benefits, health care costs and cost-
effectiveness of specified interventions. It synthesises and
estimates evidence on cost-effectiveness analysis and cost-
utility analysis within the countries. The model is used to
project the differences in quality adjusted life years
(QALYs), lifetime health-care costs and as a consequence of
interventions incremental cost effectiveness ratios (ICERs).
Sensitivity analysis is also done within this model. Outputs
can be discounted for any specific discount rate.
Qualitative analysis
Audio recordings will be transcribed verbatim by an
external agency, checked for accuracy and imported into
NVivo, along with the original audio files. Basic descrip-
tive variables will be imported from the main trial data-
base to analyse the interview and diary data. Initial
analysis using a limited set of codes drawn directly from
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questions used in the topic guide will be conducted by
at least two members of the team to ensure general reli-
ability and appropriateness of categories. Analysis will
then proceed iteratively in order to remain sensitive to
the richness of data itself and develop a detailed hier-
archy of emerging themes that address more implicit,
and cross-cutting issues that emerge through the open-
nature of the interviews. Exploiting the dynamic capacity
of NVivo software, these themes will serve as the basis
for comparison between participants. Analysis of the
overall dataset will consequently enable both a narrative-
based account of individual experiences, but also the
extent to which they are intervention specific.
Discussion
With one quarter of adults defined as clinically obese,
and with growing financial pressures on health services,
this trial will provide important information on the use
of commercial providers to deliver weight management
services in partnership with health professionals. Find-
ings will provide transparent information about treat-
ment and outcomes and will enable formation of clear
guidance for commissioners and referring practitioners.
Guidance for commissioners from the Department of
Health in England currently recommends 12 week inter-
ventions. While there is some evidence that longer inter-
ventions might improve weight loss, this evidence is
inconsistent and generally comes from indirect compari-
sons between studies. Changing current practice to in-
clude longer referrals would require evidence of both
greater clinical effectiveness and cost-effectiveness at a
population level.
While the quantitative data in this study can provide
guidance on the clinical and cost-effectiveness of the
treatment, qualitative data will elucidate some key issues
surrounding commercial partnerships, in particular pa-
tient perceptions regarding the acceptability of these
interventions. This data will also provide insight into
what participants perceive are the active ingredients of
these interventions and what patients want weight ma-
nagement services to provide.
Data on psychosocial factors can be used to identify
inter-individual differences in weight trajectories and
could potentially be used to assist in stratifying patients
to treatments likely to be effective. Data on changes in
these factors during and following the intervention, and
their association with weight trajectories, could poten-
tially be used to inform improvements in existing inter-
ventions and the development of new interventions.
This trial endeavours to evaluate how effective this
intervention would be in routine clinical practice, rather
than under optimal controlled conditions. However, the
conditions of this trial differ somewhat from those of
routine clinical practice. Firstly, participants are recruited
by letter and all participants who meet inclusion criteria
and are invited. Thus our sample may be more
heterogenous than those who a GP refers following a
face-to-face consultation. Secondly, in two of the
research centres, participants attend a research centre for
their initial intervention allocation and all assessments.
This enables greater control over data quality and partici-
pant follow-up, but differs from how the intervention
would be rolled out in primary care.
Weight loss studies are notorious for high attrition,
which can compromise the analysis and interpretation of
data. While every effort will be made to enable partici-
pants to attend follow up assessments, continued partici-
pation in the trial is voluntary and we anticipate that
there will be a substantial number of people who do not
complete all measurements. However, this also reflects
what would happen in clinical practice where many
participants will not follow the programme they are
referred to, or may not return for follow-up. Data will be
analysed on an intention to treat basis. While no method
of analysis is without limitations, this should give the
best estimation of population level effectiveness.
Research governance
Ethical approval
This is version 2.9 of the trial protocol dated 28th July 2013.
The Medical Research Council is the sponsor of the trial.
This trial was registered at current controlled trials
ISRCTN85485463 on 12th October 2012. Ethical approval
was received from NRES Committee East of England -
Cambridge East (12/EE/0363) and local approvals from
NRES Committee North West - Liverpool Central
(12/NW/0678) and NRES Committee South Central –
Oxford 12/SC/0508. Local NHS Research and Develop-
ment approvals were received for all participating
practices.
Study sponsor
The Medical Research Council (MRC) will carry out the
role of sponsor, with MRC Human Nutrition Research
(HNR) the lead unit, in accordance with the Research
Governance Framework and will take on responsibility for
securing the arrangements to initiate, manage and finance
(subject to funding) the study, and to ensure any risks are
identified and managed and that the research is of high
quality. MRC HNR has been certified since January 2006 to
the quality management standard ISO9001:2008 by Lloyds
Register QA and is subject to twice yearly external audit.
Trial steering committee
The Trial Steering Committee (TSC) is chaired by Prof
Martin Roland, Professor of Health Services Research in
the University of Cambridge. Martin is Director of the
National Primary Care Research and Development centre,
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Special Advisor to RAND Europe and has been a practising
GP for over 30 years. Other independent members include:
Prof Nick Finer, who is Honorary Professor at UCL and
Consultant Endocrinologist at University College London
Hospitals and one of the leading UK specialists in obesity
management who has been a co-author in numerous
obesity-related trials; Dr Judith Dawson, a full-time GP and
Locality Lead for GP Commissioning in Northampton; and
two patient/public representatives, Mrs Norma Scullion
and Mr Graham Rhodes. Ms Polly Page, Director of Opera-
tions for MRC HNR and chair of the unit Research Review
Board is also a member of the TSC.
The study is not blinded and carries low risk with no
rules for early termination, so it is felt that it is neither
necessary nor appropriate to have a specific Data Moni-
toring and Ethics Committee in addition to the TSC.
Data handling and quality assurance
Participation will be under full informed consent, including
for the storage and use of data collected. The Principal
Investigator (PI) will be responsible for ensuring compli-
ance with the Data Protection Act. Data collection forms
will be kept in locked cabinets and an online database with
secure encrypted transmission will be established by the
database manager, accessible remotely by designated user-
names and passwords and automatically backed up to
ensure no loss of data. The PI and Trial Coordinator will
monitor the accuracy of the database with validation checks
against the data collection forms. All resulting datasets will
be anonymised and stored securely.
Research dissemination and data preservation for sharing
The investigators will analyse data according to pre-defined
analysis plans in a timely manner. For those analyses de-
scribed in this proposal this will be within the lifetime of
the grant. The PI shall ensure that the results of the trial
will be submitted for publication in a peer reviewed journal,
regardless of the outcome. Authorship of publications will
be determined by ICMJE guidelines. As project partners,
Weight Watchers understand that they will have no influ-
ence on the data analyses or publications, but they will be
able to see publications 14 days prior to submission to
check any factual information relating to the company. All
scientific papers and reports are peer reviewed by the HNR
Research Review Board and signed off before publication.
A lay summary of the research findings will also be sent to
participants and participating primary care practices at the
end of the study.
MRC HNR will be custodians of the data resulting
from the study and will ensure compliance with the Data
Protection Act and the MRC policy for data sharing and
preservation. The HNR database manager will take
responsibility for data curation and archiving and all
data sets will be kept securely with no access from
unauthorised personnel. Data will be stored so that it
can be accessed, used and understood by subsequent
users. When the investigators have completed their
planned analyses, the anonymised data will be made
available for use by others and will be shared under
appropriate data sharing agreements. Primary data and
the Trial Master File will be retained securely in their
original form for a minimum of 10 years.
The commercial programme intervention will be deli-
vered by an employee of company and the company will
provide data on meeting attendance and website usage,
but they will have no role in the study design, data
analysis, data interpretation, or writing of the report.
Trial status
Ongoing. Recruitment was completed in February 2014.
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